Abstract
In the past decade there has been considerable progress in the characterization of individual human P450 enzymes. These advances were initiated by early work on the purification of individual enzymes from human liver and other sources. The early work in the area was guided by a focus on the most abundant and easily purified enzymes.1–4It is now apparent, in retrospect, that these proteins were in the 2C and 3A families. Efforts were shifted to attempts to purify individual P450s on the basis of catalytic activities with the evidence that in some cases a single P450 could be identified in this way; e.g., the P450 now known as P450 2D6 was found to be under monogenic control. 5 The approach is technically demanding because of the need to do separations in the presence of detergents and then remove them before analysis of catalytic activity. Nevertheless, human P450s 1A1,6 1A2,7 2A6,8 2C8,9 2C9,9,10 2D67,11,12 2E1 13,14 3A4,15 3A5,16 4A11,17 and lanosterol 14α-demethylase18 were isolated in this general manner. Another approach that has been used, sometimes in a mode complementary to catalytic specificity, is purification on the basis of immunochemical similarity to animal P450s. 7,11,19,20
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Wang, P., Mason, P. S., and Guengerich, F. P., 1980, Purification of human liver cytochrome P-450 and comparison to the enzyme isolated from rat liver, Arch. Biochem. Biophys. 199: 206–219.
Beaune, P., Dansette, P., Flinois, J. P., Columelli, S., Mansuy, D., and Leroux, J. P., 1979, Partial purification of human liver cytochrome P-450, Biochem. Biophys. Res. Commun. 88: 826–832.
Kitada, M., and Kamataki, T., 1979, Partial purification and properties of cytochrome P450 from homogenates of human fetal livers, Biochem. Pharmacol. 28: 793–797.
Wang, P. P., Beaune, P., Kaminsky, L. S., Dannan, G. A., Kadlubar, F. F., Larrey, D., and Guengerich, F. P., 1983, Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes, Biochemistry 22: 5375–5383.
Smith, R. L., Idle, J. R., Mahgoub, A. A., Sloan, T. P., and Lancaster, R.,1978, Genetically determined defects of oxidation at carbon centres of drugs, Lancet 1: 943–944.
Shimada, T., Yun, C.-H., Yamazaki, H., Gautier, J.-C., Beaune, P. H., and Guengerich, F. P., 1992, Characterization of human lung microsomal cytochrome P-450 1Al and its role in the oxidation of chemical carcinogens, Mol. Pharmacal. 41: 856–864.
Distlerath, L. M., Reilly, P. E. B., Martin, M. V., Davis, G. G., Wilkinson, G. R., and Guengerich, F. P., 1985, Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism, J. Biol. Chem. 260: 9057–9067.
Yun, C.-H., Shimada, T., and Guengerich, F. P., 1991, Purification and characterization of human liver microsomal cytochrome P-450 2A6, Mol. Pharmacol. 40: 679–685.
Ged, C., Umbenhauer, D. R., Bellew, T. M., Bork, R. W., Srivastava, P. K., Shinriki, N., Lloyd, R. S., and Guengerich, F. P., 1988, Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4’-hydroxylase, Biochemistry 27: 6929–6940.
Shimada, T., Misono, K. S., and Guengerich, F. P., 1986, Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction, J. Biol. Chem. 261: 909–921.
Gut, J., Catin, T., Dayer, P., Kronbach, T., Zanger, U., and Meyer, U.A., 1986, Debrisoquine/sparteine-type polymorphism of drug oxidation: Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol, J. Biol. Chem. 261: 11734–11743.
Birgersson, C., Morgan, E. T., Jömvall, H., and von Bahr, C., 1986, Purification of a desmethylimipramine and debrisoquine hydroxylating cytochrome P-450 from human liver, Biochem. Pharmacol. 35: 3165–3166.
Wrighton, S. A., Thomas, P. E., Ryan, D. E., and Levin, W., 1987, Purification and characterization of ethanol-inducible human hepatic cytochrome P-450HLj, Arch. Biochem. Biophys. 258: 292–297.
Guengerich, F. P., Kim, D.-H., and Iwasaki, M., 1991, Role of human cytochrome P-450 IIE1 in the oxidation of several low molecular weight cancer suspects, Chem. Res. Toxicol. 4: 168–179.
Guengerich, F. R, Martin, M. V., Beaune, P. H., Kremers, P., Wolff, T., and Waxman, D. J., 1986, Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism, J. Biol. Chem. 261: 5051–5060.
Wrighton, S.A., and VandenBranden, M., 1989, Isolation and characterization of human fetal liver cytochrome P450HLp2: A third member of the P450III gene family, Arch. Biochem. Biophys. 268: 144–151.
Kawashima, H., Kusunose, E., Kubota, I., Maekawa, M., and Kusunose, M., 1992, Purification and NHs-terminal amino acid sequences of human and rat kidney fatty acid tu-hydroxylases, Biochim. Biophys. Acta 1123: 156–162.
Sonoda, Y., Endo, M., Ishida, K., Sato, Y., Fukusen, N., and Fukuhara, M., 1993, Purification of a human P-450 isozyme catalyzing lanosterol 14a-demethylation, Biochim. Biophys. Acta 1170: 92–97.
Watkins, P. B., Wrighton, S. A., Maurel, P., Schuetz, E. G., Mendez-Picon, G., Parker, G. A., and Guzelian, P. S., 1985, Identification of an inducible form of cytochrome P-450 in human liver, Proc. Natl. Acad. Sci. USA 82: 6310–6314.
Mimura, M., Baba, T., Yamazaki, Y., Ohmori, S., Inui, Y., Gonzalez, F. J., Guengerich, F. R, and Shimada, T., 1993, Characterization of cytochrome P450 2B6 in human liver microsomes, Drug Metab. Dispos 21: 1048–1056.
Gonzalez, F. J., 1989, The molecular biology of cytochrome P450s, Pharmacol. Rev. 40: 243–288.
Nelson, D. R., Kamataki, T., Waxman, D. J., Guengerich, F. R, Estabrook, R. W., Feyereisen, R., Gonzalez, F. J., Coon, M. J., Gunsalus, I. C., Gotoh, O., Okuda, K., and Nebert, D. W., 1993, The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature, DNA Cell Biol. 12: 1–51.
Tateishi, T., Krivoruk, Y., Wood, A. J. J., Guengerich, F. R, and Wood, M., 1994, Identification of human liver P450 3A4 as the enzyme responsible for sulfentanil N-dealkylation, in: Abstracts, 12th Int. Congr. Pharmacol. (July 24–29, Montreal).
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., and Guengerich, F. R, 1994, Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians, J. Pharmacol. Exp. Ther. 270: 414–423.
Omura, T., and Sato, R., 1964, The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature, J. Biol. Chem. 239: 2370–2378.
Nakamura, K., Goto, E, Ray, W. A., McAllister, C. B., Jacqz, E., Wilkinson, G. R., and Branch, R. A., 1985, Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations, Clin. Pharmacol. Thee. 38: 402–408.
Relling, M. V., Cherrie, J., Schell, M. J., Petros, W. P., Meyer, W. H., and Evans, W. E., 1991, Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects, Clin. Pharmacol. Ther. 50: 308–313.
Keeney, D.S., and Waterman, M. R., 1993, Regulation of steroid hydroxylase gene expression: Importance to physiology and disease, Pharmacol. Ther. 58: 301–317.
Guengerich, F. P., and Shimada, T., 1991, Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes, Chem. Res. Toxicol. 4: 391–407.
Sesardic, D., Boobis, A., Murray, B., Murray, S., Segura, J., De La Torre, R., and Davies, D., 1990, Furafylline is a potent and selective inhibitor of cytochrome P450 lA2 in man, Br. J. Clin. Pharmacol. 29: 651–663.
Kunze, K. L., and Trager, W. F., 1993, Isoform-selective mechanism-based inhibition of human cytochrome-P450 1A2 by furafylline, Chem. Res. Toxicol. 6: 649–656.
Gallagher, E. P., Wienkers, L. C., Stapleton, P. L., Kunze, K. L., and Eaton, D. L., 1994, Role of human microsomal and human complementary DNA-expressed cytochrome-P4501A2 and cytochromeP4503A4 in the bioactivation of aflatoxin Bt, Cancer Res. 54: 101–108.
Hammons, G. J., Milton, D., Guengerich, F. P., Tukey, R. H., and Kadlubar, E F., 1994, Human cytochrome P450 1A2-catalyzed N-hydroxylation of carcinogenic heterocyclic amines, FASEB J. 8: A1381.
Guengerich, E P., Wang, P., and Davidson, N. K., 1982, Estimation of isozymes of microsomal cytochrome P-450 in rats, rabbits, and humans using immunochemical staining coupled with sodium dodecyl sulfate-polyacrylamide gel electrophoresis, Biochemistry 21: 1698–1706.
Beaune, P., Kremers, P. G., Kaminsky, L. S., de Graeve, J., and Guengerich, E R, 1986, Comparison of monooxygenase activities and cytochrome P-450 isozyme concentrations in human liver microsomes, Drug Metab. Dispos. 14: 437–442.
Shet, M. S., Fisher, C. W., Holmans, P. L., and Estabrook, R. W., 1993, Human cytochrome P450 3A4: Enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase, Proc. Natl. Acad. Sci. USA 90: 11748–11752.
Wang, R. W., Kari, P. H., Lu, A.Y.H., Thomas, P. E., Guengerich, F. R, and Vyas, K. R, 1991, Biotransformation of lovastatin. IV. Identification of cytochrome P-450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes, Arch. Biochem. Biophys. 290: 355–361.
Guengerich, F. R, 1990, Mechanism-based inactivation of human liver cytochrome P-450 IIIA4 by gestodene, Chem. Res. Toxicol. 3: 363–371.
Distlerath, L. M., and Guengerich, F. P., 1984, Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs using antibodies raised to the analogous rat enzyme, Proc. Natl. Acad. Sci. USA 81: 7348–7352.
Guo, Z., Gillam, E.M.J., Ohmori, S., Tukey, R. H., and Guengerich, F. R, 1995, Expression of modified human cytochrome P450 1A1 in Escherichia coli. Effects of 5’ substitution, purification, spectral characterization, reconstitution conditions and catalytic properties, Arch. Biochem. Biophys. 317: 374384.
Edwards, R. J., Singleton, A. M., Sesardic, D., Boobis, A. R., and Davies, D. S., 1988, Antibodies to a synthetic peptide that react specifically with a common surface region on two hydrocarbon-inducible isoenzymes of cytochrome P-450 in the rat, Biochem. Pharmacol. 37: 3735–3741.
Fujino, T., Park, S. S., West, D., and Gelboin, H. V., 1982, Phenotyping of cytochromes P-450 in human tissues with monoclonal antibodies, Proc. Natl. Acad. Sci. USA 79: 3682–3686.
Reik, L. M., Levin, W., Ryan, D. E., Maines, S. L., and Thomas, R E., 1985, Monoclonal antibodies distinguish among isozymes of the cytochrome P-450b subfamily, Arch. Biochem. Biophys. 242:365-382.
Gelboin, H. V., and Friedman, F. K., 1985, Monoclonal antibodies for studies on xenobiotic and endobiotic metabolism, Biochem. Pharmacol. 34: 2225–2234.
Goldfarb, I., Korzekwa, K., Krausz, K. W., Gonzalez, F., and Gelboin, H. V., 1993, Cross-reactivity of thirteen monoclonal antibodies with ten vaccinia cDNA expressed rat, mouse and human cytochrome P450s, Biochem. Pharmacol. 46: 787–790.
Wrighton, S. A., VandenBranden, M., Becker, G. W., Black, S. D., and Thomas, P. E., 1992, Two monoclonal antibodies recognizing different epitomes on rat cytochrome P450 IIB1 react with human IIE!, Mol. Pharmacol. 41: 76–82.
Wrighton, S. A., Stevens, J. C., Becker, G. W., and VandenBranden, M., 1993, Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and 5-mephenytoin 4’-hydroxylation, Arch. Biochem. Biophys. 306: 240–245.
Soucek, P., Guo, Z., Sandhu, P., Martin, M. V., and Guengerich, F. P., 1994, Immunochemical cross-reactivity of human cytochrome P450 enzymes analyzed with recombinant proteins, FASEB J. 8:Al248.
Wrighton, S. A., and Stevens, J. C., 1992, The human hepatic cytochromes P450 involved in drug metabolism, Crit. Rev. Toxicol. 22: 1–21.
Oeda, K., Sakaki, T., and Ohkawa, H., 1985, Expression of rat liver cytochrome P-450MC cDNA in Saccharomyces cerevisiae, DNA 4: 203–210.
Zuber, M. X., Simpson, E. R., and Waterman, M. R., 1986, Expression of bovine 17a-hydroxylase cytochrome P-450 cDNA in nonsteroidogenic (COS 1) cells, Science 234: 1258–1261.
Gonzalez, F. J., Kimura, S., Tamura, S., and Gelboin, H. V., 1991, Expression of mammalian cytochrome P450 using baculovirus, Methods Enzymol. 206: 93–99.
Guengerich, F. P., Brian, W. R., Sari, M.-A., and Ross, J.-T., 1991, Expression of mammalian cytochrome P450 enzymes using yeast-based vectors, Methods Enzymol. 206: 130–145.
Gonzalez, F. J., Aoyama, T., and Gelboin, H. V., 1991, Expression of mammalian cytochrome P450 using vaccinia virus, Methods Enzymol. 206: 85–92.
Clark, B. J., and Waterman, M. R., 1991, Heterologous expression of mammalian P450 in COS cells, Methods Enzymol. 206: 100–108.
Porter, T. D., and Larson, J. R., 1991, Expression of mammalian P450s in Escherichia coli, Methods Enzymol. 206: 108–116.
Doehmer, J., and Oesch, F., 1991, V79 Chinese hamster cells genetically engineered for stable expression of cytochromes P450, Methods Enzymol. 206: 117–123.
Crespi, C. L., 1991, Expression of cytochrome P450 cDNAs in human B lymphoblastoid cells: Applications to toxicology and metabolite analysis, Methods Enzymol. 206: 123–129.
Imai, Y., and Nakamura, M., 1989, Point mutations at threonine-301 modify substrate specificity of rabbit liver microsomal cytochromes P-450 (laurate (w-1)-hydroxylase and testosterone 16a-hydroxylase), Biochem. Biophys. Res. Commun. 158: 717–722.
Gill am, E. M. J., Baba, T., Kim, B.-R., Ohmori, S., and Guengerich, E R, 1993, Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme, Arch. Biochem. Biophys. 305: 123–131.
Sandhu, R, Baba, T., and Guengerich, F. P., 1993, Expression of modified cytochrome P450 2C10 in Escherichia coli, purification, and reconstitution of catalytic activity, Arch. Biochem. Biophys. 306: 443–450.
Sandhu, P., Guo, Z., Baba, T., Martin, M. V., Tukey, R. H., and Guengerich, E R, 1994, Expression of modified human cytochrome P450 1A2 in Escherichia coli. Stabilization, purification, characterization, and catalytic activities of the enzyme, Arch. Biochem. Biophys. 309: 168–177.
Gillam, E.M.J., Guo, Z., and Guengerich, F R, 1994, Expression of modified human cytochrome P450 2E1 in Escherichia coli, purification, and spectral and catalytic properties, Arch. Biochem. Biophys. 312: 59–66.
Sakaki, T., Oeda, K., Yabusaki, Y., and Ohkawa, H., 1986, Monooxygenase activity of Saccharomyces cerevisiae cells transformed with expression plasmids carrying rat cytochrome P-450MC cDNA, J. Biochem. 99: 741–749.
Dogra, S., Doehmer, J., Glatt, H., Molders, H., Siegert, P., Friedberg, T., Seidel, A., and Oesch, F., 1990, Stable expression of rat cytochrome P-450IA1 cDNA in V79 Chinese hamster cells and their use in mutagenicity testing, Mol. Pharmacol. 37: 608–613.
Fisher, C. W., Shet, M. S., Caudle, D. L., Martin-Wixtrom, C.A., and Estabrook, R. W., 1992, High-level expression in Escherichia coli of enzymatically active fusion proteins containing the domains of mammalian cytochromes P450 and NADPH-P450 reductase flavoprotein, Proc. Natl. Acad. Sci. USA 89: 10817–10821.
Morel, F., Beaune, P. H., Ratanasavanh, D., Flinois, J.-P., Yang, C.-S., Guengerich, F. P., and Guillouzo, A., 1990, Expression of cytochrome P-450 enzymes in cultured human hepatocytes, Eur. J. Biochem. 191: 437–444.
Dahlin, D. C., Miwa, G. T., Lu, A.Y. H., and Nelson, S. D., 1984, N-Acetyl-p-benzoquinone imine: A cytochrome P-450-mediated oxidation product of acetaminophen, Proc. Natl. Acad. Sci. USA 81: 1327–1331.
Higashi, Y., Hiromasa, T., Tanae, A., Miki, T., Nakura, J., Kondo, T., Ohura, T., Ogawa, E., Nakayama, K., and Fujii-Kuriyama, Y., 1991, Effects of individual mutations in the P-450n (C21) pseudogene on the P-450 (C21) activity and their distribution in the patient genomes of congenital steroid 21-hydroxylase deficiency, J. Biochem. 109: 638–644.
Miller, W.L., and Morel, Y., 1989, The molecular genetics of 21-hydroxylase deficiency, Annu. Rev. Genet. 23: 371–393.
White, P. C., Dupont, J., New, M. I., Leiberman, E., Hochberg, Z., and Rösler, A., 1991, A mutation in CYP11Ba (Arg 448-H is) associated with steroid 11(3-hydroxylase deficiency in Jews of Moroccan origin, J. Clin. Invest. 87: 1664–1667.
Distlerath, L. M., and Guengerich, E P., 1987, Enzymology of human liver cytochromes P-450, in: Mammalian Cytochromes P-450, Vol. 1 ( F. P. Guengerich, ed.), CRC Press, Boca Raton, FL, pp. 133–198.
Tinel, M., Belghiti, J., Descatoire, V., Amouyal, G., Letteron, P., Geneve, J., Larrey, D., and Pessayre, D., 1987, Inactivation of human liver cytochrome P-450 by the drug methoxsalen and other psoralen derivatives, Biochem. Pharmacol. 36: 951–955.
Ortiz de Montellano, P. R., and Correia, M. A., 1983, Suicidal destruction of cytochrome P-450 during oxidative drug metabolism, Annu. Rev. Pharmacol. Toxicol. 23: 481–503.
Bailey, D. G., Spence, J. D., Munoz, C., and Arnold, J. M. O., 1991, Interaction of citrus juices with felodipine and nifedipine, Lancet 337: 268–269.
Barbeau, A., Roy, M., Bernier, G., Campanella, G., and Paris, S., 1987, Ecogenetics of Parkinson’s disease: Prevalence and environmental aspects in rural areas, Can. J. Neurol. Sci. 14: 36–41.
Barbeau, A., Roy, M., Paris, S., Cloutier, T., Plasse, L., and Poirier, J.,1985, Ecogenetics of Parkinson’s disease: 4-Hydroxylation of debrisoquine, Lancet 11: 1213–1215.
Armstrong, M., Daly, A. K., Cholerton, S., Bateman, D. N., and Idle, J. R., 1992, Mutant debrisoquine hydroxylation genes in Parkinson’s disease, Lancet 339: 1017–1018.
Fonne-Pfister, R., Bargetzi, M. J., and Meyer, U. A., 1987, MPTP, the neurotoxin inducing Parkinson’s disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufl, P450dbl) catalyzing debrisoquine 4-hydroxylation, Biochem. Biophys. Res. Commun. 148: 1144 1150.
Ayesh, R., Idle, J. R., Ritchie, J. C., Crothers, M. J., and Hetzel, M. R., 1984, Metabolic oxidation phenotypes as markers for susceptibility to lung cancer, Nature 312: 169–170.
Idle, J. R., Armstrong, M., Boddy, A. V., Boustead, C., Cholerton, S., Cooper, J., Daly, A. K., Ellis, J., Gregory, W., Hadidi, H., Höfer, C., Holt, J., Leathart, J., McCracken, N., Monkman, S. C., Painter, J. E., Taber, H., Walker, D., and Yule, M., 1992, The pharmacogenetics of chemical carcinogenesis, Pharmacogenetics 2: 246–258.
Sugimura, H., Caporaso, N. E., Shaw, G. L., Modali, R. V., Gonzalez, F. J., Hoover, R. N., Resau, J. H., Trump, B. F., Weston, A., and Harris, C. C., 1990, Human debrisoquine hydroxylase gene polymorphisms in cancer patients and controls, Carcinogenesis 11: 1527–1530.
Kaisary, A., Smith, P., Jaczq, E., McAllister, C. B., Wilkinson, G. R, Ray, W. A., and Branch, R. A., 1987, Genetic predisposition to bladder cancer: Ability to hydroxylate debrisoquine and mephenytoin as risk factors, Cancer Res. 47: 5488–5493.
Law, M. R., Hetzel, M. R., and Idle, J. R., 1989, Debrisoquine metabolism and genetic predisposition to lung cancer, Br. J Cancer 54: 686–687.
Caporaso, N. E., Tucker, M. A., Hoover, R. N., Hayes, R. B., Pickle, L. W., Issaq, H. J., Muschik, G. M., Green-Gallo, L., Buivys, D., Aisner, S., Resau, J. H., Trump, B. F., Tollerud, D., Weston, A., and Harris, C. C., 1990, Lung cancer and the debrisoquine metabolic phenotype, J. Natl. Cancer Inst. 82: 1264–1271.
Wolff, T., Distlerath, L. M., Worthington, M. T., Groopman, J. D., Hammons, G. J., Kadlubar, F. F., Prough, R. A., Martin, M. V., and Guengerich, F. P., 1985, Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling, Cancer Res. 45: 2116–2122.
Shimada, T., and Guengerich, F. P., 1991, Activation of amino-a-carboline, 2-amino-1-methyl-6phenylimidazo[4,5-b]pyridine, and a copper phthalocyanine cellulose extract of cigarette smoke condensate by cytochrome P450 enzymes in rat and human liver microsomes, Cancer Res. 51: 5284–5291.
Roots, I., Drakoulis, N., and Brockmöller, J., 1993, Still an open question: Does active CYP2D6 predispose to lung cancer? in: 8th International Conference on Cytochrome P450: Biochemistry, Biophysics, and Molecular Biology (October 24–28, Lisbon), p. 159.
Ritter, J., Somasundaram, R., Heinemeyer, G., and Roots, I., 1986, The debrisoquine hydroxylation phenotype and the acetylator phenotype as genetic risk factors for the occurrence of larynx and pharynx carcinoma, Acta Pharmacol. Toxicol. 59 (Suppl. 5): 221.
Drakoulis, N., Minks, T., Ploch, M., Otte, F., Heinemeyer, G., Kampf, D., Loddenkemper, R., and Roots, I., 1986, Questionable association of debrisoquine hydroxylator phenotype and risk for bronchial carcinoma, Acta Pharmacol. Toxicol. 59 (Suppl. 5): 220.
Speirs, C. J., Murray, S., Davies, D. S., Mabadeje, A. E B., and Boobis, A. R., 1990, Debrisoquine oxidation phenotype and susceptibility to lung cancer, Br. J. Clin. Pharmacol. 29: 101–109.
Ladero, J. M., Benitez, J., Gonzalez, J. E, Vargas, E., and Díaz-Rubio, M., 1991, Oxidative polymorphism of debrisoquine is not related to human colo-rectal cancer, Eur. J. Clin. Pharmacol. 40: 525–527.
Caporaso, N. E., Shields, P. G., Landi, M. T., Shaw, G. L., Tucker, M. A., Hoover, M., Sugimura, H., Weston, A., and Harris, C. C., 1992, The debrisoquine metabolic phenotype and DNA-based assays: Implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype, Environ. Health Perspect. 98: 101–105.
Waller, D. G., Renwick, A. G., Gruchy, B. S., and George, C. F., 1984, The first pass metabolism of nifedipine in man, Br. J. Clin. Pharmacol. 18: 951–954.
Kaminsky, L.S., and Fasco, M. J., 1992, Small intestinal cytochromes P450, Crit. Rev. Toxicol. 21: 407–422.
Kolars, J. C., Schmiedlin-Ren, P., Schuetz, J. D., Fang, C., and Watkins, P. B., 1992, Identification of rifampin-inducible P450II1A4 (CYP3A4) in human small bowel enterocytes, J. Clin. Invest. 90: 1871–1878.
Meese, C. O., Fischer, C., Kupfer, A., Wisser, H., and Eichelbaum, M., 1991, Identification of the “major” polymorphic carbocysteine metabolite as S-(carboxymethylthio)-L-cysteine, Biochem. Pharmacol. 42: R13 - R16.
TLrgeon, D. K., Normolle, D. P., Leichtman, A. B., Annesley, T. M., Smith, D. E., and Watkins, P. B., 1992, Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients, Clin. Pharmacol. Ther. 52: 471–478.
Cresteil, T., and Eisen, H.J., 1988, Regulation of human cytochrome P1–450 gene, in: Liver Cells and Drugs, Colloque INSERM ( A. Guillouzo, ed.), INSERM/John Libbey Erotext Ltd., London, pp. 51–58.
Schweikl, H., Taylor, J. A., Kitareewan, S., Linko, P., Nagorney, D., and Goldstein, J. A., 1993, Expression of CYPIAJ and CYPIA2 genes in human liver, Pharmacogenetics 3: 239–249.
Kellerman, G., Luyten-Kellerman, M., and Shaw, C. R., 1973, Genetic variation of aryl hydrocarbon hydroxylase in human lymphocytes, Am. J. Hum. Genet. 25: 327–331.
Kellerman, G., Shaw, C. R., and Luyten-Kellerman, M., 1973, Aryl hydrocarbon hydroxylase inducibility and bronchogenic carcinoma, N. Engl. J Med. 298: 934–937.
Paigen, B., Ward, E., Reilly, A., Houten, L., Gurtoo, H. L., Minowada, J., Steenland, K., Havens, M. B., and Sartori, P., 1981, Seasonal variation of aryl hydrocarbon hydroxylase activity in human lymphocytes, Cancer Res. 41: 2757–2761.
Leboeuf, R., Havens, M., Tabron, D., and Paigen, B., 1981, Arylhydrocarbon hydroxylase activity and cytochrome P-450 in human tissues, Biochim. Biophys. Acta 658: 348–355.
Kouri, R. E., McKinney, C. E., Levine, A. S., Edwards, B. K., Vesell, E. S., Nebert, D. W., and McLemore, T. L., 1984, Variations in aryl hydrocarbon hydroxylase activities in mitogen-activated human and nonhuman primate lymphocytes, Toxicol. Pathol. 12: 44–48.
Kouri, R. E., McKinney, C. E., Slomiany, D. J., Snodgrass, D. R., Wray, N. P., and McLemore, T. L., 1982, Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes, Cancer Res. 42: 5030–5037.
McLemore, T. L., Adelberg, S., Liu, M. C., McMahon, N. A., Yu, S. J., Hubbard, W.C., Czerwinski, M., Wood, T. G., Storeng, R., Lubet, R. A., Eggleston, J. C., Boyd, M.R., and Hines, R. N., 1990, Expression of CYP1A1 gene in patients with lung cancer: Evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas, J. Natl. Cancer Inst. 82: 1333–1339.
Hayashi, S., Watanabe, J., Nakachi, K., and Kawajiri, K., 1991, Genetic linkage of lung cancer-associated Mspl polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene, J. Biochem. 110: 407–411.
Tefre, T., Ryberg, D., Haugen, A., Nebert, D. W., Skaug, V., Brogger, A., and Borresen, A. L., 1991, Human CYP1A 1(cytochrome P1450) gene: Lack of association between the Msp I restriction fragment length polymorphism and incidence of lung cancer in a Norwegian population, Pharmacogenetics 1: 20–25.
Hirvonen, A., Husgafvel-Pursiainen, K., Karjalainen, A., Anttila, S., and Vainio, H., 1992, Point-mutational Mspl and Ile-Val polymorphisms closely linked in the CYP1A1 gene: Lack of association with susceptibility to lung cancer in a Finnish study population, Cancer Epidemiol. Biomarkers Prey. 1: 485–489.
Hayashi, S. I., Watanabe, J., Nakachi, K., and Kawajiri, K., 1991, PCR detection of an A/G polymorphism within exon 7 of the CYPIA1 gene, Nucl. Acids Res. 19: 4797.
Drakoulis, N., Cascorbi, I., Brockmöller, J., Gross, C. R., and Roots, I., 1993, Exon-7 point mutation (M2; 4889A>G) in human CYP1A1 gene as susceptibility factor for lung cancer, in: 8th International Conference on Cytochrome P450: Biochemistry, Biophysics, and Molecular Biology (October 24–28, Lisbon, Portugal ), p. 204.
Wedlund, R. J., Kimura, S., Gonzalez, F. J., and Nebert, D. W., 1994, I462V mutation in the human CYP1A1 gene: Lack of correlation with either the Msp I 1.9 kb (M2) allele or CYPIA1 inducibility in a three-generation family of East Mediterranean descent, Pharmacogenetics 4: 21–26.
Crofts, F., Cosma, G. N., Currie, D., Taioli, E., Toniolo, R, and Garte, S. J., 1993, A novel CYP1A1 gene polymorphism in African-Americans, Carcinogenesis 14: 1729–1731.
Roberts-Thomson, S. J., McManus, M. E., Tukey, R. H., Gonzalez, F. J., and Holder, G. M., 1993, The catalytic activity of four expressed human cytochrome P450s towards benzo[a]pyrene and the isomers of its proximate carcinogen, Biochem. Biophys. Res. Commun. 192: 1373–1379.
Shimada, T., Martin, M. V., Pruess-Schwartz, D., Marnett, L. J., and Guengerich, F. R, 1989, Roles of individual human cytochrome P450 enzymes in the bioactivation of benzo(a)pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycydic aromatic hydrocarbons, Cancer Res. 49: 6304–6312.
Yun, C.-H., Shimada, T., and Guengerich, F. P., 1992, Roles of human liver cytochrome P-4502C and 3A enzymes in the 3-hydroxylation of benzo(a)pyrene, Cancer Res. 52: 1868–1874.
McManus, M. E., Burgess, W. M., Veronese, M. E., Huggett, A., Quattrochi, L. C., and Tukey, R. H., 1990, Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochromes P-450, Cancer Res. 50: 3367–3376.
Eugster, H. P., Sengstag, C., Meyer, U. A., Hinnen, A., and Wiirgler, F. E., 1990, Constitutive and inducible expression of human cytochrome P450IA1 in yeast Saccharomyces cerevisiae: An alternative enzyme source for in vitro studies, Biochem. Biophys. Res. Commun. 172: 737–744.
Ching, M. S., Lennard, M. S., Tucker, G. T., Woods, H. E, Kelly, D. E., and Kelly, S. L., 1991, The expression of human cytochrome P450IA1 in the yeast Saccharomyces cerevisiae, Biochem. Pharmacol. 42: 753–758.
Renaud, J. P., Peyronneau, M. A., Urban, P., Truan, G., Cullin, C., Pompon, D., Beaune, P., and Mansuy, D., 1993, Recombinant yeast in drug metabolism, Toxicology 182: 39–52.
Simon, I., Berthou, F., Riche, C., Beaune, P., and Ratanasavanh, D., 1993, Both cytochrome P4501A and 3A4 are involved in the N-demethylation of tamoxifen, in: Abstracts, 5th Europenn ISSX Meeting (September 26–29, Tours), Vol. 3, p. 44.
Berthou, E, Carriere, V., Ratanasavanh, D., Goasduff, T., Morel, F., Gautier, J. C., Guillouzo, A., and Beaune, P., 1993, On the specificity of chlorzoxazone as drug probe of cytochrome P4502E1, in: Abstracts, 5th European ISSX Meeting (September 26–29, Tours), Vol. 3, p. 116.
Farin, F. M., and Omiecinski, C. J., 1993, Regiospecific expression of cytochrome P-450s and microsomal epoxide hydrolase in human brain tissue, J. Toxicol. Environ. Health 40: 317–335.
Whitlock, J. P., Jr., 1993, Mechanistic aspects of dioxin action, Chem. Res. Toxicol. 6: 754–763.
Quattrochi, L. C., Vu, T., and Tukey, R. H., 1994, The human CYP1A2 gene and induction by 3-methylcholanthrene. A region of DNA that supports Ah-receptor binding and promoter-specific induction, J. Biol. Chem. 269: 6949–6954.
Butler, M. A., Iwasaki, M., Guengerich, F. P., and Kadlubar, F. F., 1989, Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines, Proc. Natl. Acad. Sci. USA 86: 7696–7700.
Butler, M. A., Lang, N. P., Young, J. F., Caporaso, N. E., Vineis, P., Hayes, R. B., Teitel, C. H., Massengill, J. P., Lawsen, M. F., and Kadlubar, E F., 1992, Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites, Pharmacogenetics 2: 116–127.
Vesell, E.S., and Penno, M. B., 1984, A new polymorphism of hepatic drug oxidation in humans: Family studies of antipyrine metabolites, Fed. Proc. 43: 2342–2347.
Engel, G., Knebel, N. G., Hofmann, U., and Eichelbaum, M., 1992, In vitro characterization of human cytochrome P450-enzymes involved in antipyrine metabolism, in: Abstracts, 23rd European Workshop on Drug Metabolism (September 21–25, Bergamo).
Lang, N. P., Butler, M. A., Massengill, J., Lawson, M., Stotts, R. C., Hauer-Jensen, M., and Kadlubar, F. E, 1994, Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increases the risk for colorectal cancer or polyps, Cancer Epidemiol. Biomarkers Prey. 3: 675–682.
Kalow, W., and Tang, B. K., 1993, The use of caffeine for enzyme assays: A critical appraisal, Clin. Pharmacol. Ther. 53: 503–514.
Gu, L., Gonzalez, F. J., Kalow, W., and Tang, B. K., 1992, Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E 1, Pharmacogenetics 2: 73–77.
Robson, R. A., Matthews, A. R, Miners, J. O., McManus, M. E., Meyer, U. A., Hall, R. de la M., and Birken, D. J., 1987, Characterisation of theophylline metabolism in human liver microsomes, Br. J. Clin. Pharmacol. 24: 293–300.
Patten, C., Thomas, P. E., Guy, R., Lee, M., Gonzalez, F. J., Guengerich, F. P., and Yang, C. S., 1993, Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics, Chem. Res. Toxicol. 6: 511–518.
Dahlqvist, R., Bertilsson, L., Birkett, D. J., Eichelbaum, M., Säwe, J., and Sjöqvist, P., 1984, Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism, Clin. Pharmacol. Titer. 35: 815–821.
Yamazaki, H., Guo, Z., Mimura, M., Gonzalez, F. J., Sugahara, C., Guengerich, E P., and Shimada, T., 1994, Bufuralol hydroxylation by cytochrome P450 2D6, 1A1, and 1A2 enzymes in human liver microsomes, Mol. Pharmacol. 46: 568–577.
Woolf, T. F., Pool, W. F., Kukan, M., Bezek, S., Kunze, K., and Trager, W. F., 1993, Characterization of tacrine metabolism and bioactivation using heterologous expression systems and inhibition studies: Evidence for CYP 1 A2 involvement, in: Abstracts, 5th North American ISSX Meeting (October 17–21, Tucson), Vol. 4, p. 139.
Kunze, K. L., Wienkers, L. C., Thutmnel, K. E., and Trager, W. F., 1993, The use of furafylline together with li ver screening techniques and enzyme kinetics to evaluate the role of P450 1 A2 in the metabolism of theophylline at therapeutic concentrations in human liver, in: Abstracts, 5th North American ISSX Meeting (October 17–21, Tucson), Vol. 4, p. 138.
Rettie, A. E., Korzekwa, K. R., Kunze, K. L., Lawrence, R. E, Eddy, A. C., Aoyama, T., Gelboin, H. V., Gonzalez, F. J., and Trager, W. F., 1992, Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin drug interactions, Chem. Res. Toxicol. 5: 54–59.
Feldman, C. H., Hutchinson, V. E., Pippenger, C. E., Blemenfeld, T. A., Feldman, B. R., and Davis, W. J., 1980, Effect of dietary protein and carbohydrate on theophylline metabolism in children, Pediatrics 66: 956–962.
Diaz, D., Fabre, I., Daujat, M., Saintaubert, B., Bories, P., Michel, H., and Maurel, P., 1990, Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome-P450, Gastroenterology 99: 737–747.
Quattrochi, L. C., and Tukey, R. H., 1993, Nuclear uptake of the Ah (dionan) receptor in response to omeprazole: Transcriptional activation of the human CYP1A1 gene, Mol. Pharmacol. 43: 504–508.
Rost, K. L., and Roots, I., 1993, Accelerated caffeine metabolism after omeprazole treatment in breath, plasma, and urine, in: 8th International Conference on Cytochrome P450: Biochemistry, Biophysics, and Molecular Biology (October 24–28, Lisbon), p. 203.
Fisher, C. W., Caudle, D. L., Martin-Wixtrom, C., Quattrochi, L. C., Tukey, R. H., Waterman, M. R., and Estabrook, R. W., 1992, High-level expression of functional cytochrome P450 1A2 in Escherichia coli, FASEB J. 6: 759–764.
Kadlubar, P. F., and Hammons, G. J., 1987, The role of cytochrome P-450 in the metabolism of chemical carcinogens, in: Mammalian Cytochromes P-450, Vol. 2 (F. P. Guengerich, ed.), CRC Press, Boca Raton, FL, pp. 81–130.
Sugimura, T., 1992, Multistep carcinogenesis: A 1992 perspective, Science 258: 603–607.
Crespi, C. L., Steimel, D. T., Aoyama, T., Gelboin, H. V., and Gonzalez, F. J., 1990, Stable expression of human cytochrome P450IA2 cDNA in a human lymphoblastoid cell line: Role of the enzyme in the metabolic activation of aflatoxin Bi, Mol. Carcinog. 3: 5–8.
Glatt, H. R., Pauly, K., Wölfel, C., Dogra, S., Seidel, A., Lee, H., Harvey, R. G., Oesch, F., and Doehmer, J., 1993, Stable expression of heterologous cytochromes P450 in V79 cells: Mutagenicity studies with polycyclic aromatic hydrocarbons, in: Polycyclic Aromatic Compounds: Synthesis, Properties, Analytical Measurements, Occurrence and Biological Effects. (Proceedings of the Thirteenth International Symposium on Polynuclear Aromatic Hydrocarbons, October 1–4, 1991, Bordeaux, France) ( P. Garrigues and M. Lamotte, eds.) Gordon and Breach, New York pp. 1167–1174.
Savas, U., Bhattacharyya, K. K., Christou, M., Alexander, D. L., and Jefcoate, C. R., 1994, Mouse cytochrome P450EF, representative of a new 1B subfamily of cytochrome P450s. Cloning, sequence determination, and tissue expression, J. Biol. Chem. 264: 14905–14911.
Sutter, T. R, Tang, Y. M., Hayes, C. L., Wo, Y-Y. P., Jabs, E. W., Li, X., Yin, H., Cody, C. S., and Greenlee, W. F., 1994, Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2, J. Biol. Chem. 269: 1309213099.
Yamano, S., Tatsuno, J., and Gonzalez, F. J., 1990, The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes, Biochemistry 29: 1322–1329.
Miles, J. S., McLaren, A. W., Forrester, L. M., Glancey, M. J., Lang, M. A., and Wolf, C. R., 1990, Identification of the human liver cytochrome P450 responsible for coumarin 7-hydroxylase activity, Biochem. J. 267: 365–371.
Daly, A. K., Cholerton, S., Gregory, W., and Idle, J. R., 1993, Metabolic polymorphisms, Pharmacol. Ther. 57: 129–160.
Cholerton, S., Idle, M. E., Vas, A., Gonzalez, F. J., and Idle, J. R., 1992, Comparison of a novel thin-layer chromatographic—fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine, J. Chromatogr. 575: 325–330.
Daly, A. K., Cholerton, S., Armstrong, M., and Idle, J. R., 1994, Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility, Environ. Health Perspect. 102: 55–61.
Rautio, A., Kraul, H., Kojo, A., Salmela, E., and Pelkonen, 0., 1992, Interindividual variability of coumarin 7-hydroxylation in healthy volunteers, Pharmacogenetics 2: 227–233.
Crespi, C. L., Penman, B. W., Steimel, D. T., Gelboin, H. V., and Gonzalez, F. J., 1991, The development of a human cell line stably expressing human CYP3A4: Role in the metabolic activation of aflatoxin Bi and comparison to CYPIA2 and CYP2A3, Carcinogenesis 12: 355–359.
Crespi, C. L., Penman, B. W., Leakey, J.A.E., Arlotto, M. P., Stark, A., Parkinson, A., Turner, T., Steimel, D. T., Rudo, K., Davies, R. L., and Langenbach, R., 1990, Human cytochrome P4501IA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1, Carcinogenesis 11: 1293–1300.
Yamazaki, H., Inui, Y., Yun, C. H., Mimura, M., Guengerich, E P., and Shimada, T., 1992, Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes, Carcinogenesis 13: 1789–1794.
Smith, T. J., Guo, Z., Gonzalez, P. J., Guengerich, E P., Stoner, G. D., and Yang, C. S., 1992, Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human lung and liver microsomes and cytochromes P-450 expressed in hepatoma cells, Cancer Res. 52: 1757–1763.
Crespi, C. L., Penman, B. W., Gelboin, H. V., and Gonzalez, F. J., 1991, A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6, Carcinogenesis 12:1197-1201.
Hong, J. Y., Ding, X., Smith, T. J., Coon, M. J., and Yang, C. S., 1992, Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a tobacco-specific carcinogen, by rabbit nasal microsomes and cytochrome P405s NMa and NMb, Carcinogenesis 13: 2141–2144.
Haugen, D. A., van der Hoeven, T. A., and Coon, M. J., 1975, Purified liver microsomal cytochrome P-450: Separation and characterization of multiple forms, J. Biol. Chem. 250: 3567–3570.
Imai, Y., and Sato, R., 1974, A gel-electrophoretically homogeneous preparation of cytochrome P-450 from liver microsomes of phenobarbital-pretreated rabbits, Biochem. Biophys. Res. Commun. 60: 814.
Guengerich, F. P., 1978, Separation and purification of multiple forms of microsomal cytochrome P-450. Partial characterization of three apparently homogeneous cytochromes P-450 prepared from livers of phenobarbital-and 3-methylcholanthrene-treated rats, J. Biol. Chem. 253: 7931–7939.
Ryan, D. E., Thomas, P. E., Korzeniowski, D., and Levin, W., 1979, Separation and characterization of highly purified forms of liver microsomal cytochrome P-450 from rats treated with polychlorinated biphenyls, phenobarbital, and 3-methylcholanthrene, J. Biol. Chem. 254: 1365–1374.
Yamano, S., Nhamburo, P. T., Aoyama, T., Meyer, U. A., Inaba, T., Kalow, W., Gelboin, H. V., McBride, 0. W., and Gonzalez, F. J., 1989, cDNA cloning and sequence and cDNA-directed expression of human P450 IIB1: Identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver, Biochemistry 28:7340–7348.
Flammang, A. M., Gelboin, H. V., Aoyama, T., Gonzalez, F. J., and McCoy, G. D., 1992, Nicotine metabolism by cDNA-expressed human cytochrome P-450s, Biochem. Arch. 8: 1–8.
Leo, M. A., Lasker, J. M., Raucy, J. L., Kim, C. I., Black, M., and Lieber, C. S., 1989, Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC8, A rch. Biochem. Biophys. 269: 305–312.
Wrighton, S. A., Thomas, P. E., Willis, P., Maines, S. L., Watkins, R. B., Levin, W., and Guzelian, P. S., 1987, Purification of a human liver cytochrome P-450 immunochemically related to several cytochromes P-450 purified from untreated rats, J. Clin. Invest. 80: 1017–1022.
Okino, S. T., Quattrochi, L. C., Pendurthi, U. R., McBride, O. W., and Tukey, R. H., 1987, Characterization of multiple human cytochrome P450 1 cDNAs, J. Biol. Chem. 262: 16072–16079.
Kimura, S., Pastewka, J., Gelboin, H. V., and Gonzalez, F. J., 1987, cDNA and amino acid sequences of two members of the human P450I1C gene subfamily, Nucl. Acids Res. 15: 10053
Harris, J. W., Rahman, A., Kim, B.-R., Guengerich, F. R. and Collins, J. M., 1994, Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and of an unknown P450 enzyme, Cancer Res. 54: 4026–4035.
Cosme, J., Maurel, R, Soucek, R, Guengerich, F. R, and Beaune, R. H., 1994, Cloning, expression and characterization of human cytochrome P-450 2C8 in heterologous systems, Abstracts, 14th European Drug Metabolism Workshop (July 3–8, Paris).
Romkes, M., Faletto, M. B., Blaisdell, J. A., Raucy, J. L., and Goldstein, J. A., 1991, Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily, Biochemistry 30: 3247–3255.
Brian, W. R., Srivastava, P. K., Umbenhauer, D. R., Lloyd, R. S., and Guengerich, F. R, 1989, Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae, Biochemistry 28: 4993–4999.
Relling, M. V., Aoyama, T., Gonzalez, F. J., and Meyer, U. A., 1990, Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily, J. Pharmacol. Exp. Ther. 252: 442–447.
Lopez Garcia, M. R, Dansette, R. M., Valadon, R, Amar, C., Beaune, P. H., Guengerich, F. R, and Mansuy, D., 1993, Human liver P450s expressed in yeast as tools for reactive metabolite formation studies: Oxidative activation of tienilic acid by P450 2C9 and P450 2C10, Eur. J. Biochem. 213: 223–232.
Veronese, M. E., Mackenzie, R. I., Doecke, C. J., McManus, M. E., Miners, J. O., and Birken, D. J., 1991, Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9, Biochem. Biophys. Res. Commun. 175: 1112–1118.
Zilly, W., Breimer, D. D., and Richter, E., 1977, Stimulation of drug metabolism by rifampicin in patients with cirrhosis or cholestasis measured by increased hexobarbital and tolbutamide clearance, Eur. J. Clin. Pharmacol. 11: 287–293.
Vasko, M. R., Bell, R. D., Daly, D. D., and Pippenger, C. E., 1980, Inheritance of phenytoin hypometabolism: A kinetic study of one family, Clin. Pharmacol. Ther. 27: 96–103.
Scott, J., and Poffenbarger, R. L., 1978, Pharmacogenetics of tolbutamide metabolism in humans, Diabetes 28: 41–51.
Umbenhauer, D. R., Martin, M. V., Lloyd, R. S., and Guengerich, F. P., 1987, Cloning and sequence determination of a complementary DNA related to human liver microsomal cytochrome P-450 S-mephenytoin 4-hydroxylase, Biochemistry 26: 1094–1099.
Srivastava, P. K., Yun, C.-H., Beaune, R H., Ged, C., and Guengerich, F. R, 1991, Separation of human liver tolbutamine hydroxylase and (S)-mephenytoin 4’-hydroxylase cytochrome P-450 enzymes, Mol. Pharmacol. 40: 69–79.
Kato, R., Yasumori, T., Nagata, K., Yang, S. K., Chen, L. S., Murayama, N., and Yamazoe, Y., 1993, Oxidative metabolism of diazepam in human liver: Differential role of CYP2C and CYP3A depending on substrate concentration, in: 8th International Conference on Cytochrome P450: Biochemistry, Biophysics, and Molecular Biology (October 24–28, Lisbon), p. 241.
Yasumori, T., Nagata, K., Yang, S. K., Chen, L.-S., Murayama, N., Yamazoe, Y., and Kato, R., 1993, Cytochrome P450 mediated metabolism of diazepam in human and rat: Involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner, Pharmacogenetics 3: 291–301.
Leeman, T., Transon, C., and Dayer, P., 1993, Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4’-hydroxylation in human liver, Life Sci. 52: 29–34.
Knodell, R. G., Dubey, R. K., Wilkinson, G. R., and Guengerich, F. P., 1988, Oxidative metabolism of hexobarbital in human liver: Relationship to polymorphic S-mephenytoin 4-hydroxylation, J. Pharmacol. Exp. Ther. 245: 845–849.
Leeman, T. D., Transon, C., Bonnabry, P., and Dayer, P., 1993, A major role for cytochrome P450m (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs, Drugs Exp. Clin. Res. 19: 189–195.
Stearns, R. A., Chakravarty, P. K., Chen, R., and Chiu, S.H.L., 1993, Investigations into the mechanism of oxidation of losartan, an alcohol, to its active metabolite, a carboxylic acid derivative, in: Abstracts, 5th North American ISSX Meeting (October 17–21, Tucson), Vol. 4, p. 238.
Kupfer, A., and Branch, R. A., 1985, Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation, Clin. Pharmacol. Ther. 38: 414–418.
Hall, S. D., Guengerich, F. P., Branch, R. A., and Wilkinson, G. R., 1987, Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes, J. Pharmacol. Exp. Ther. 240: 216–222.
Andersson, T., Regârdh, C. G., Dahl-Puustinen, M. L., and Bertilsson, L., 1990, Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators, Ther. Drug Monitoring 12: 415–416.
Curi-Pedrosa, R., Pichard, L., Bonfils, C., Jacqz-Aigrain, E., Guengerich, F. R, and Maurel, P., 1993, Major implication of cytochrome P450 3A4 in the oxidative metabolism of antisecretory drugs omeprazole and lansoprazole in human liver microsomes and hepatocytes, in: Abstracts, 5th European ISSX Meeting (September 26–29, Tours), Vol. 3, p. 46.
Knodell, R. G., Hall, S. D., Wilkinson, G. R., and Guengerich, F. R, 1987, Hepatic metabolism of tolbutamide: Characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition, J. Pharmacol. Exp. Ther. 241: 1112–1119.
Nakamura, M., Tanaka, E., Misawa, S., Shimada, T., Imaoka, S., and Funae, Y., 1994, Trimethadione metabolism, a useful indicator for assessing hepatic drug-oxidizing capacity, Biochem. Pharmacol. 47: 247–251.
Furuya, H., Meyer, U. A., Gelboin, H. V., and Gonzalez, F. J., 1991, Polymerase chain reaction-directed identification, cloning, and quantification of human CYP2C18 mRNA, Mol. Pharmacol. 40: 375–382.
Yasumori, T., Murayama, N., Yamazoe, Y., Nogi, Y., Fukasawa, T., and Kato, R., 1989, Expression of a human P-4501íC gene in yeast cells using galactose-inducible expression system, Mol. Pharmacol. 35: 443–449.
Goldstein, J. A., Faletto, M. B., Romkessparks, M., Sullivan, T., Kitareewan, S., Raucy, J. L., Lasker, J. M., and Ghanayem, B. I., 1994, Evidence that CYP2C19 is the major (S)-mephenytoin 4’hydroxylase in humans, Biochemistry 33: 1743–1752.
Wedlund, R. J., Aslanian, W. S., McAllister, C. B., Wilkinson, G. R., and Branch, R. A., 1984, Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism, Clin. Pharmacol. Ther. 36: 773–780.
Kupfer, A., and Preisig, R., 1984, Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man, Eur. J. Clin. Phnrmacol. 26: 753–759.
Miners, J. O., Smith, K. J., Robson, R. A., McManus, M. E., Veronese, M. E., and Birkett, D. J., 1988, Tolbutamide hydroxylation by human liver microsomes: Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations, Biochem. Pharmacol. 37: 1137–1144.
Gonzalez, E J., Skoda, R. C., Kimura, S., Umeno, M., Zanger, U. M., Neben, D. W., Gelboin, H. V., Hardwick, J. P., and Meyer, U. A., 1988, Characterization of the common genetic defect in humans deficient in debrisoquine metabolism, Nature 331: 442–446.
Kimura, S., Umeno, M., Skoda, R. C., Meyer, U. A., and Gonzalez, F. J.,1989, The human debrisoquine 4-hydroxylase (CYP2D) locus: Sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene, Am. J. Hum. Genet. 45: 889–904.
Idle, J. R., Mahgoub, A., Lancaster, R., and Smith, R. L., 1978, Hypotensive response to debrisoquine and hydroxylation phenotype, Life Sci. 22: 979–984.
Eichelbaum, M., Spannbrucker, N., Steincke, B., and Dengler, H. J., 1979, Defective N-oxidation of sparteine in man: A new pharmacogenetic defect, Eur. J. Clin. Pharmacol. 16: 183–187.
Lennard, M. S., Silas, J. H., Freestone, S., Tucker, G. T., Ramsay, L. E., and Woods, H. F., 1982, Impaired metabolism of metoprolol in poor hydroxylators of debrisoquine, Br. J. Pharmscol. 16: 572P - 573 P.
Bertilsson, L., Eichelbaum, M., Mellström, B., Säwe, J., Schulz, H. U., and Sjögvist, E, 1980, Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man, Life Sci. 27: 1673–1677.
Larrey, D., Distlerath, L. M., Dannan, G. A., Wilkinson, G. R., and Guengerich, F. P., 1984, Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism, Biochemistry 23: 2787–2795.
Gonzalez, E J., Matsunaga, T., Nagata, K., Meyer, U. A., Nebert, D. W., Pastewka, J., Kozak, C. A., Gillette, J., Gelboin, H. V., and Hardwick, J. P., 1987, Debrisoquine 4-hydroxylase: Characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism, DNA 6: 149–161.
Matsunaga, E., Zanger, U. M., Hardwick, J. P., Gelboin, H. V., Meyer, U. A., and Gonzalez, F. J., 1989, The CYP2D gene subfamily: Analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA rats, Biochemistry 28: 7349–7355.
Gut, J., Gasser, R., Dayer, P., Kronbach, T., Catin, T., and Meyer, U. A., 1984, Debrisoquine-type polymorphism of drug oxidation: Purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation, FEBS Lett. 173: 287–290.
Skoda, R. C., Gonzalez, F. J., Demierre, A., and Meyer, U. A., 1988, Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs, Proc. Natl. Acad. Sci. USA 85: 5240–5243.
Tyndale, R., Aoyama, T., Broly, F., Matsunaga, T., Inaba, T., Kalow, W., Gelboin, H. V., Meyer, U. A., and Gonzalez, F. J., 1991, Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: Possible association with the poor metabolizer phenotype, Pharmacogenetics 1: 26–32.
Armstrong, M., Fairbrother, K., Idle, J. R., and Daly, A. K., 1994, The cytochrome P450 CYP2D6 allelic variant CYPD6J and related polymorphisms in a European population, Pharmacogenetics 4 73–81.
Armstrong, M., Idle, J. R., and Daly, A. K., 1993, A polymorphic CfoI site in exon 6 of the human cytochrome P50 CYP2D6 gene detected by the polymerase chain reaction, Hum. Genet. 91: 616–617.
Gonzalez, F. J., and Meyer, U. A., 1991, Molecular genetics of the debrisoquin-sparteine polymorphism, Clin. Pharmacol. Ther. 50: 233–238.
Gough, A. C., Miles, J. S., Spurr, N. K., Moss, J. E., Gaedigk, A., Eichelbaum, M., and Wolf, C. R., 1990, Identification of the primary gene defect at the cytochrome P450 CYP2D locus, Nature 347: 773–776.
Heim, M., and Meyer, U. A., 1990, Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification, Lancet 336: 529–532.
Daly, A. K., Armstrong, M., Monkman, S. C., Idle, M. E., and Idle, J. R., 1991, Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes, Pharmacogenetics 1: 33–41.
Evans, W. E., Relling, M. V., Rahman, A., McLeod, H. L., Scott, E. P., and Lin, J. S., 1993, Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans, J. Clin. Invest. 91: 2150–2154.
Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M. L., Sjoqvist, F., and Ingelman-Sundberg, M. 1993, Inherited amplification of an active gene in the cytochrome-P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine, Proc. Natl. Acad. Sci. USA. 90: 11825–11829.
Matsunaga, E., Zeugin, T., Zanger, U. M., Aoyama, T., Meyer, U. A., and Gonzalez, F. J., 1990, Setuence requirements for cytochrome P-450IID1 catalytic activity: A single amino acid change (Ile-80 Phe) specifically decreases V. of the enzyme for bufuralol but not debrisoquine hydroxylation, J. Biol. Chem. 265: 17197–17201.
Köppel, C., Tenczer, J., and Arndt, I., 1989, Metabolic disposition of ajmaline, Eur. J. Drug Metab. Pharmacokin. 14: 309–316.
Alvan, G., Grind, M., Graffner, C., and Sjöqvist, F., 1984, Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism, Clin. Pharmacol. Ther. 36: 515–519.
Mellström, B., Säwe, J., Bertilsson, L., and Sjöqvist, F., 1986, Amitriptyline metabolism: Association with debrisoquin hydroxylation in nonsmokers, Clin. Pharmacol. Ther. 39: 369–371.
Ebner, T., and Eichelbaum, M., 1993, The metabolism of apridine in relation to the sparteine/debrisoquine polymorphism, Br. J. Clin. Pharmacol. 35: 426–430.
Dayer, P., Balant, L., Kupfer, A., Striberni, R., and Leemann, T., 1985, Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol, Eur. J. Clin. Pharmacol. 28: 317–320.
Pressacco, J., Muller, R., and Kalow, W., 1993, Interactions of bupranolol with the polymorphic debrisoquine/spearteine monooxygenase (CYP2D6), Eur J, Clin. Pharmacol. 45: 261–264.
Gleiter, C. H., Aichele, G., Nilsson, E., Hengen, N., Antonin, K. H., and Bieck, P. R., 1985, Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development, Br. J. Clin. Pharmacol. 20: 81–84.
Balant-Gorgia, A. E., Balant, L. P., Genet, C., Dayer, P., Aeschlimann, J. M., and Garrone, G., 1986, Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites, Eue J. Clin. Pharmacol. 31: 449–455.
Fischer, V., Vogels, B., Maurer, G., and Tynes, R. E., 1992, The anti psychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6, J. Pharmacol. Exp. Ther. 260: 1355–1360.
Dayer, P., Desmeules, J., Leemann, T., and Striberni, R., 1988, Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation, Biochem. Biophys. Res. Commun. 152: 411–416.
Tucker, G. T., Silas, J. H., Iyun, A. O., Lennard, M. S., and Smith, A. J., 1977, Polymorphic hydroxylation of debrisoquine, Lancet. 11: 718.
Evans, D.A.P., Harmer, D., Downham, D. Y., Whibley, E. J., Idle, J. R, Ritchie, J., and Smith, R. L., 1983, The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions, J. Med. Genet. 20: 321–329.
Mahgoub, A., Idle, J. R., Dring, L. G., Lancaster, R., and Smith, R. L., 1977, Polymorphic hydroxylation of debrisoquine in man, Lancet 11: 584–586.
Broly, F., Gaedigk, A., Heim, M., Eichelbaum, M., Morike, K., and Meyer, U. A., 1991, Debrisoquine/sparteine hydroxylation genotype and phenotype: Analysis of common mutations and alleles of CYP2D6 in a European population, DNA Cell Biol. 10: 545–558.
Grace, J. M., Kinter, M. T., and Macdonald, T.L., 1994, Atypical metabolism of deprenyl and its enantiomer, (S)-(+)N,a-dimethyl-N-propynylphenethylamine, by cytochrome P450 2D6, Chem. Res. Toxicol. 7: 286–290.
Spina, E., Steiner, E., Ericsson, Ö., and Sjöqvist, F., 1987, Hydroxylation of desmethylimipramine: Dependence on the debrisoquin hydroxylation phenotype, Clin. Pharmacol. Ther. 41: 314–319.
Coulter, C., Sanzgiri, U., and Parkinson, A., 1993, Evidence for the involvement of CYP3A enzymes in the N-demethylation of dextromethorphan, in: Abstracts, 5th North American ISSX Meeting (October 17–21, Tucson), Vol. 4, p. 183.
Mortimer, O., Lindström, B., Laurell, H., Bergman, U., and Rane, A., 1989, Dextromethorphan: Polymorphic serum pattern of the 0-demethylated and didemethylated metabolites in man, Br. J. Clin. Pharmacol. 27: 223–227.
Küpfer, A., Schmid, B., Preisig, R., and Pfaff, G., 1984, Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism, Lancet 11: 517–518.
Woosley, R. L., Roden, D. M., Dai, G., Wang, T., Altenbern, D., Oates, J., and Wilkinson, G. R., 1986, Co-inheritance of the polymorphic metabolism of encainide and debrisoquin, Clin. Pharmacol. Ther. 39: 282–287.
Gross, A. S., Mikus, G., Fischer, C., Hertrampf, R, Gundert-Remy, U., and Eichelbaum, M., 1989, Stereoselective disposition of flecainide in relation to the sparteine debrisoquine metaboliser phenotype, Br. J. Clin. Pharmacol. 28: 555–566.
Sloan, P., Mahgoub, A., Lancaster, R., Idle, J. R., and Smith, R. L., 1978, Polymorphism of carbon oxidation of drugs and clinical implications, Br. Med. J. 2: 655–657.
Subramanyam, B., Woolf, T., and Castagnoli, N., Jr., 1991, Studies on the in vitro conversion of haloperidol to a potentially neurotoxic pyridinium metabolite, Chem. Res. Toxicol. 4: 123–128.
Otton, S. V., Schadel, M., Cheung, S. W., Kaplan, H. L., Busto, U. E., and Sellers, E. M., 1993, CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone, Clin. Pharmacol. Ther. 54: 463–472.
Lemoine, A., Gautier, J. C., Azoulay, D., Guengerich, F. P., Beaune, P., Maurel, P., and Leroux, J. P., 1993, The major pathway of imipramine metabolism is catalyzed by cytochrome P-450 1 A2 and P-450 3A4 in human liver, Mol. Pharmacol. 43: 827–832.
Pierce, D. M., 1990, A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin, Xenobiotica 20: 1357–1367.
Dow, J. D., Laucher-Harsany, V., and Haegele, K. D., 1993, In vitro studies on the metabolism of the putative anxiolytic MDL 73005 using human liver microsomes and microsomes prepared from cells expressing a single human cytochrome P-450 isozyme, in: Abstracts, 5th European ISSX Meeting (September 26–29, Tours), Vol. 3, p. 48.
Kitchen, I., Tremblay, J., Andre, J., Dring, L. G., Idle, J. R., Smith, R. L., and Williams, R. T., 1979, Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine, Xenobiotica 9: 397–404.
Roy, S. D., Hawes, E. M., McKay, G., Korchinski, E. D., and Midha, K. K., 1985, Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin, Clin. Pharmacol. Ther. 38: 128–133.
Ellis, S. W., Ching, M. S., Watson, P. F., Henderson, C. J., Simula, A. P., Lennard, M. S., Tucker, G. T., and Woods, H. F., 1992, Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast, Biochem. Pharmacol. 44: 617–620.
Lennard, M. S., Silas, J. H., Freestone, S., Ramsay, L. E., Tucker, G. T., and Woods, H. F., 1982, Oxidation phenotype—A major determinant of metoprolol metabolism and response, N. Engl. J. Med. 307: 1558–1560.
Turgeon, J., Fiset, C., Giguère, R., Gilbert, M., Moerike, K., Rouleau, J. R., Kroemer, H. K., Eichelbaum, M., Grech-Bélanger, O., and Bélanger, P. M., 1991, Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man, J. Pharmacol. Exp. Ther. 259: 789–798.
Marre, T., Fabre, G., Lacarelle, B., Bourrie, M., Catalin, J., Berger, Y., Rahmani, R., and Cano, J. P., 1992, Involvement of the cytochrome P-450IID subfamily in minaprine 4-hydroxylation by human microsomes, Drug Metab. Dispos. 20: 316–321.
Bertilsson, L., Mellström, B., Sjöqvist, F., M$rtensson, B., and Asberg, M., 1981, Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: Clinical implications, Lancet 11: 560–561.
Bloomer, J. C., Woods, P. R., Haddock, R. E., Lennard, M. S., and Tucker, G. T., 1992, The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes, Br. J. Clin. Pharmacol. 33: 521–523.
Shah, R. R., Oates, N. S., Idle, J. R., Smith, R. L., and Lockhart, J.D.F., 1982, Impaired oxidation of debrisoquine in patients with perhexiline neuropathy, Br. Med. J. 284: 295–299.
Dahl-Puustinen, M. L., Lidén, A., Alm, C., Nordin, C., and Bertilsson, L., 1989, Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings, Clin. Pharmacol. Ther. 46: 78–81.
Oates, N. S., Shah, R. R., Idle, J. R., and Smith, R. L., 1981, Phenfornún-induced lactic acidosis associated with impaired debrisoquine hydroxylation, Lancet i:837–838.
Kroemer, H. K., Fischer, C., Meese, C. O., and Eichelbaum, M., 1991, Enantiomer–enantiomer interaction of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: In vitro evaluation of the mechanism, Mol. Pharmacol. 40: 135–142.
Lee, J. T., Kroemer, H. K., Silberstein, D. J., Funck-Brentano, C., Lineberry, M. D., Wood, A. J. J., Roden, D. M., and Woosley, R. L., 1990, The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone, N. Engl. J. Med. 322: 1764–1768.
Zekorn, C., Achtert, G., Hausleiter, H. J., Moon, C. H., and Eichelbaum, M., 1985, Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation, K(in. Wochenschr. 63: 1180–1186.
Shaw, L., Lennard, M. S., Tucker, G. T., Bax, N.D.S., and Woods, H. E, 1987, Irreversible binding and metabolism of propranolol by human liver microsomes—relationship to polymorphic oxidation, Biochem. Pharmacol. 36: 2283–2288.
Osikowska-Evers, B., Dayer, P., Meyer, U. A., Robertz, G. E, and Eichelbaum, M., 1987, Evidence for altered catalytic properties of the cytochrome P-450 involved in sparteine oxidation in poor metabolizers, Clin. Pharmacol. Ther. 41: 320–325.
Baumann, P., Meyer, J. W., Amey, M., Baettig, D., Bryois, C., Jonzier-Perey, M., Koeb, L., Monney, C., and Woggon, B., 1992, Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline, Ther. Drug Monitor. 14: 1–8.
McGourty, J. C., Silas, J. H., Fleming, J. J., McBurney, A., and Ward, J. W., 1985, Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin, Clin. Pharmacol. Ther. 38: 409–413.
Lewis, R. V., Lennard, M. S., Jackson, P. R., Tucker, G. T., Ramsay, L. E., and Woods, H. E, 1985, Timolol and atenolol: Relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics, Br. J. Clin. Pharmacol. 19: 329–333.
Otton, S. V., Inaba, T., and Kalow, W., 1984, Competitive inhibition of sparteine oxidation in human liver by (3-adrenoceptor antagonists and other cardiovascular drugs, Life Sci. 34: 73–80.
Fonne-Pfister, R., and Meyer, U. A., 1988, Xenobiotic and endobiotic inhibitors of cytochrome P-450db1 function, the target of the debrisoquine/sparteine type polymorphism, Biochem. Pharmacol. 37: 3829–3835.
Strobl, G. R., von Kruedener, S., Stöckigt, J., Guengerich, F. P., and Wolff, T., 1993, Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: Molecular modeling and inhibition studies, J. Med. Chem. 36: 1136–1145.
Inaba, T., Tyndale, R. E., and Mahon, W. A., 1986, Quinidine: Potent inhibition of sparteine and debrisoquine oxidation in vivo, Br. J. Clin. Pharmacol. 22: 199–200.
Leemann, T., Dayer, P., and Meyer, U. A., 1986, Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers, Eur. J. Clin. Pharmacol. 29: 739–741.
Mikus, G., Bochner, F., Eichelbaum, M., Horak, P., Somogyi, A. A., and Spector, S., 1994, Endogenous codeine and morphine in poor and extensive metabolisers of the YP2D6 (debrisoquine/sparteine) polymorphism, J. Pharmacol. Exp. Ther. 268: 546–551.
Islam, S. A., Wolf, C. R., Lennard, M. S., and Sternberg, M.J.E., 1991, A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation, Carcinogenesis 12: 2211–2219.
Koymans, L., Vermeulen, N.P.E., van Acker, S.A.B.E., te Koppele, J. M., Heykants, J.J.P., Lavrijsen, K., Meuldermans, W., and Donné-Op den Kelder, G. M., 1992, A predictive model for substrates of cytochrome P450-debrisoquine (2D6), Chem. Res. Toxicol. 5: 211–219.
Guengerich, F. P., Müller-Enoch, D., and Blair, I. A., 1986, Oxidation of quinidine by human liver cytochrome P-450, Mol. Pharmacol. 30: 287–295.
Macdonald, T. L., Gutheim, W.G., Martin, R. B., and Guengerich, F. P., 1989, Oxidation of substituted N,N-dimethylanilines by cytochrome P-450: Estimation of the effective oxidation—reduction potential of cytochrome P-450, Biochemistry 28: 2071–2077.
Niznik, H. B., Tyndale, R. F., Sallee, E R., Gonzalez, F. J., Hardwick, J. P., Inaba, T., and Kalow, W., 1990, The dopamine transporter and cytochrome P450I1D1 (debrisoquine 4-hydroxylase) in brain: Resolution and identification of two distinct [1H]GBR-12935 binding proteins, Arch. Biochem. Biophys. 276: 424–432.
Gonzalez, F. J., and Nebert, D. W., 1990, Evolution of the P450 gene superfamily: Animal—plant `warfare,’ molecular drive and human genetic differences in drug oxidation, Trends Genet. 66: 164–168.
Idle, J. R., Mahgoub, A., Sloan, T. P., Smith, R. L., Mbanefo, C. O., andBababunmi, E. A., 1981, Some observations on the oxidation phenotype status of Nigerian patients presenting with cancer, Cancer Lett. 11: 331–338.
Barbeau, A., Roy, M., Paris, S., Cloutier, T., Plasse, L., and Poirier, J., 1985, Ecogenetics of Parkinson’s disease: 4-Hydroxylation of debrisoquine, Lancet 11: 1213–1215.
Boobis, A. R., and Davies, D. S., 1990, Debrisoquine oxidation phenotype and susceptibility to lung cancer, Br. J. Clin. Pharmacol. 30: 653–656.
Vallada, H., Collier, D., Dawson, E., Owen, M., Nanko, S., Murray, R, and Gill, M., 1992, Debrisoquine 4-hydroxylase (CYP2D) locus and possible susceptibility to schizophrenia, Lancet 340: 181–182.
Ding, X., Pemecky, S. J., and Coon, M. J., 1991, Purification and characterization of cytochrome P450 2E2 from hepatic microsomes of neonatal rabbits, Arch. Biochem. Biophys. 291: 270–276.
Koop, D. R., 1992, Oxidative and reductive metabolism by cytochrome P450 2E1, FASEB J. 6: 724–730.
Yang, C. S., Yoo, J.S.H., Ishizaki, H., and Hong, J., 1990, Cytochrome P4501IE1: Roles in nitrosamine metabolism and mechanisms of regulation, Drug Metab. Rev. 22: 147–159.
Uematsu, F., Kikuchi, H., Motomiya, M., Abe, T., Ishioka, C., Kanamaru, R, Sagami, I., and Watanabe, M., 1992, Human cytochrome P450I1E1 gene: Dral polymorphism and susceptibility to cancer, Tohoku J. Exp. Med. 168: 113–117.
Peter, R., Böcker, R. G., Beaune, P. H., Iwasaki, M., Guengerich, F. P., and Yang, C.-S., 1990, Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450 IIEi, Chem. Res. Toxicol. 3: 566–573.
Guengerich, F. P., and Turvy, C. G., 1991, Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples, J. Pharmacol. Exp. Ther. 256: 1189–1194.
Hong, J. Y., Ning, S. M., Ma, B. L., Lee, M. J., Pan, J., and Yang, C. S., 1990, Roles of pituitary hormones in the regulation of hepatic cytochrome P45011E1 in rats and mice, Arch. Biochem. Biophys. 281: 132–138.
Pan, J., Hong, J. Y., and Yang, C. S., 1992, Post-transcriptional regulation of mouse renal cytochrome P450 2E1 by testosterone, Arch. Biochem. Biophys. 299: 110–115
Ronis, M.J.J., Johansson, I., Hultenby, K., Lagercrantz, J., Glaumann, H., and Ingelman-Sundberg, M., 1991, Acetone-regulated synthesis and degradation of cytochrome P4502E and cytochrome P4502B1 in rat liver, Eur. J. Biochem. 198: 383–389.
Ingelman-Sundberg, M., and Jörnvall, H., 1984, Induction of the ethanol-inducible form of rabbit liver microsomal cytochrome P450 by inhibitors of alcohol dehydrogenase, Biochem. Biophys. Res. Commun. 124: 375–382.
Gonzalez, F. J., Kimura, S., Song, B. J., Pastewka, J., Gelboin, H. V., and Hardwick, J. P., 1986, Sequence of two related P450 mRNAs transcriptionally increased during rat development, J. Biol. Chem. 261: 10667–10672.
Song, B. J., Veech, R. L., Park, S. S., Gelboin, H. V., and Gonzalez, E. J., 1989, Induction of rat hepatic N-nitrosodimethylamine demethylase by acetone is due to protein stabilization, J. Biol. Chem. 264: 3568–3572.
Perrot, N., Nalpas, B., Yang, C. S., and Beaune, R H., 1989, Modulation of cytochrome P450 isozymes in human liver, by ethanol and drug intake, Eur. J. Clin. Invest. 19: 549–555.
Hayashi, S., Watanabe, J., and Kawajiri, K., 1991, Genetic polymorphisms in the 5’-flanking region change transcriptional regulation of the human P450IIE1 gene, J. Biochem. 110: 559–565.
Patten, C. J., Ishizaki, H., Aoyama, T., Lee, M., Ning, S. M., Huang, W., Gonzalez, F. J., and Yang, C. S., 1992, Catalytic properties of the human cytochrome P450 2E1 produced by cDNA expression in mammalian cells, Arch. Biochem. Biophys. 299: 163–171.
Mapoles, J., Berthou, F., Alexander, A., Simon, F., and Ménez, J.-F., 1993, Mammalian PC-12 cell genetically engineered for human cytochrome P450 2E1 expression, Eur. J. Biochem. 214: 735–745.
Winters, D. K., and Cederbaum, A. I., 1992, Expression of a catalytically active human cytochrome P-4502E1 in Escherichia coli, Biochem. Biophys. Acta 1156: 43–49.
Wade, D., Yang, C. S., Metral, C. J., Roman, J. M., Hrabie, J. A., Riggs, C. W., Anjo, T., Keefer, L. K., and Mico, B. A., 1987, Deuterium isotope effect on denitrosation and demethylation of N-nitrosodimethylamine by rat liver microsomes, Cancer Res. 47: 3373–3377.
Yang, C. S., Ishizaki, H., Lee, M., Wade, D., and Fadel, A., 1991, Deuterium isotope effect in the interaction of N-nitrosodimethylamine, ethanol, and related compounds with cytochrome P-450IIE1, Chem. Res. Toxicol. 4: 408–413.
Andersen, M. E., Clewell, H. J., III, Mahle, D. A., and Gearhart, J. M., 1993, Deuterium isotope effects of dichloromethane in vivo and the mechanism of substrate oxidation by cytochrome P450 2E1, Toxicol. Appl. Pharmacol. 128: 158–165.
Kharasch, E. D., Thummel, K. E., and Mautz, D., 1993, Human enflurane metabolism in vivo by cytochrome P450 2E1, in: Abstracts, 5th North American ISSX Meeting (October 17–21, Tucson), Vol. 4, p. 143.
O’Shea, D., Davis, S. N., Kim, R. B., and Wilkinson, G. R., 1994, Effect of fasting and obesity in humans on the 6-hydroxylation of chloroxazone—A putative probe of CYP2E1 activity, Clin. Pliarrnacol. The,. 56: 359–367.
Ziegler, D. M., 1988, Flavin-containing monooxygenases: Catalytic mechanism and substrate specificities, Drug Metab. Rev. 19:1–32.
Lee, S. K., Nesheim, J. C., and Lipscomb, J. D., 1993, Transient intermediates of the methane monooxygenase catalytic cycle, J. Biol. Chem. 268: 21569–21577.
Crespi, C. L., Penman, B. W., Leakey, J. A., Arlotto, M. R, Stark, A., Parkinson, A., Turner, T., Steimel, D. T., Rudo, K., Davies, R. L., and Langenbach, R., 1990, Human cytochrome P4501IA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P4501IE1, Carcinogenesis 11: 1293–1300.
Nhamburo, P. T., Kimura, S., McBride, O. W., Kozak, C. A., Gelboin, H. V., and Gonzalez, F. J., 1990, The human CYP2F gene subfamily: Identification of a cDNA encoding a new cytochrome P450, cDNA-directed expression, and chromosome mapping, Biochemistry 29: 5491–5499.
Gonzalez, F. J., and Gelboin, H. V., 1993, Role of human cytochrome P-450s in risk assessment and susceptibility to environmentally based disease, J. Toxicol. Environ. Health 40: 289–308.
Guengerich, F. P., Gillam, E. M. J., Martin, M. V., Baba, T., Kim, B. R., Shimada, T., Raney, K. D., and Yun, C. H., 1994, The importance of cytochrome P450 3A enzymes in drug metabolism, in: Schering Foundation Workshop, Assessment of the Use of Single Cytochrome P450 Enzymes in Drug Research (March 23–25, Springer-Verlag Berlin), pp 161–186.
Yun, C.-H., Wood, M., Wood, A. J. J., and Guengerich, F. P., 1992, Identification of the pharmacogenetic determinants of alfentanil metabolism: Cytochrome P-450 3A4. An explanation of the variable elimination clearance, Anesthesiology 77: 467–474.
Gillet, G., Pichard, L., Filali-Ansary, A., Thénot, J. P., and Maurel, P., 1993, Identification of the major cytochromes P450 involved in the formation of plasma metabolites of alpidem in man, in: Abstracts, 5th European ISSX Meeting (September 26–29, Tours) Vol. 3, p. 47.
Fabre, G., Julian, B., Saint-Aubert, B., Joyeux, H., and Berger, Y., 1993, Evidence for CYP3A-mediated N-deethylation of aminodarone in human liver microsomal fractions, Drug Metab. Dispos. 21: 978–985.
Guengerich, E R, Brian, W. R., Iwasaki, M., Sari, M.-A., Bäärnhielm, C., and Berntsson, R, 1991, Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 II1A4, J. Med. Chem. 34: 1838–1844.
Andersson, R, and Jönsson, G., 1993, The metabolism of budesonide in human liver is catalysed by cytochrome P450 3A isoenzymes, in: Abstracts, 5th North American ISSX Meeting (October 17–21, Tucson), Vol. 4, p. 236.
Jönsson, G., Andersson, P., and Äström, A., 1993, Budesonide is metabolised by cytochrome P4503A isoenzymes in human liver, in: 8th International Conference on Cytochrome P450: Biochemistry, Biophysics, and Molecular Biology (October 24–28, Lisbon), p. 242.
Pellinen, R, Honkakoski, P., Stenbäck, F., Niemitz, M., Alhava, E., Pelkonen, O., Lang, M., and Pasanen, M., 1994, Cocaine N-demethylation and the metabolism-related hepatotoxicity can be prevented by cytochrome P450 3A inhibitors, Eur. J. Pharmacol. Environ. Toxicol. Pharmacol. Sect. 270: 35–43.
Ged, C., Rouillon, J. M., Pichard, L., Combalbert, J., Bressot, N., Bories, R. Michel, H., Beaune, R, and Maurel, R, 1989, The increase in urinary excretion of 6ß-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction, Br. J. Clin. Pharmacol. 28: 373–387.
Brian, W. R., Sari, M.-A., Iwasaki, M., Shimada, T., Kaminsky, L. S., and Guengerich, F. R, 1990, Catalytic activities of human liver cytochrome P-450 111A4 expressed in Saccharomyces cerevisiae, Biochemistry 29: 11280–11292.
Waxman, D. J., Chang, T.K.H., and Chen, G., 1993, Role of individual human liver P450s and other enzymes in anti-cancer drug metabolism: Drug activation and drug resistance mechanisms, in: 8th International Conference on Cytochrome P450: Biochemistry, Biophysics, and Molecular Biology (October 24–28, Lisbon), p. 71.
Combalbert, J., Fabre, I., Fabre, G., Dalet, I., Derancourt, J., Cano, J. R, and Maurel, P., 1989, Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily, Drug Metab. Dispos. 17: 197–207.
Kronbach, T., Fischer, V., and Meyer, U. A., 1988, Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs, Clin. Pharmacol. Ther. 43: 630–635.
Fleming, C. M., Branch, R. A., Wilkinson, G. R., and Guengerich, F. R, 1992, Human liver microsomal N-hydroxylation of dapsone by cytochrome P450 3A4, Mol. Pharmacol. 41: 975–980.
Chauncey, M. A., and Ninomiya, S., 1990, Metabolic studies with model cytochrome P-450 systems, Tetrahedron Lett. 31: 5901–5904.
Stevens, J. C., Berger, R. L., and Bordeaux, K. G., 1993, Metabolism of ebastine by human liver microsomes and cDNA-expressed cytochrome P450 forms, in: Abstracts, 5th European ISSX Meeting (September 26–29, Tours), Vol. 3, p. 66.
Ball, S. E., Maurer, G., Zollinger, M., Ladona, M., and Vickers, A. E. M., 1992, Characterization of the cytochrome P-450 gene family responsible for the N-dealkylation of the ergot alkaloid CQA 206–291 in humans, Drug Metab. Dispos. 20: 56–63.
Kerlan, V., Dreano, Y., Bercovici, J. R, Beaune, P. H., Foch, H. H., and Berthou, F., 1992, Nature of cytochromes P450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes, Biochem. Pharmacol. 44: 1745–1756.
Waxman, D. J., Lapenson, D. P., Aoyama, T., Gelboin, H. V., Gonzalez, F. J., and Korzekwa, K., 1991, Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s, Arch. Biochem. Biophys. 290: 160–166.
Guengerich, F. R, 1988, Oxidation of 17a-ethynylestradiol by human liver cytochrome P-450, Mol. Pharmscol. 33: 500–508.
Sattler, M., Guengerich, F. R, Yun, C.-H., Christians, U., and Sewing, K. F., 1992, Human and rat liver microsomal cytochrome P450 3A enzymes are involved in biotransformation of FK506 and rapamyein, Drug Metab. Dispos. 20: 753–761.
Vincent, S. H., Karanam, B. V., Painter, S. K., and Chiu, S.H.L., 1992, In vitro metabolism of FK-506 in rat, rabbit, and human liver microsomes: Identification of a major metabolite and of cytochrome P450 3A as the major enzymes responsible for its metabolism, Arch. Biochem. Biophys. 294: 454–460.
Bargetzi, M. J., Aoyama, T., Gonzalez, F. J., and Meyer, U. A., 1989, Lidocaine metabolism in human liver microsomes by cytochrome P450II1A4, Clin. Pharniacol. Ther. 46: 421–427.
Imaoka, S., Enomoto, K., Oda, Y., Asada, A., Fujimori, M., Shimada, T., Fujita, S., Guengerich, F. R, and Funae, Y., 1990, Lidocaine metabolism by human cytochrome P-450s purified from hepatic microsomes: Comparison of those with rat hepatic cytochrome P-450s, J. Pharmacol. Exp. Ther. 255: 1385–1391.
Vyas, K. P., Kari, R. H., Pitzenberger, S. M., Wang, R. W., and Lu, A. Y. H., 1993, Identification of 3’,5’-dihydro-3’,5’-diol-A4-lovastatin as a new cytochrome P450 3A catalyzed metabolite of lovastatin in rat and human liver microsomes, in: Abstracts, 5th North American ISSX Meeting (October 17–21, Tucson), Vol. 4, p. 35.
Kronbach, T., Mathys, D., Umeno, M., Gonzalez, F. J., and Meyer, U. A., 1989, Oxidation of midazolam and triazolam by human liver cytochrome P450111A4, Mol. Pharmacol. 36: 89–96.
Böcker, R. H., and Guengerich, F. R, 1986, Oxidation of 4-aryl-and 4-alkyl-substituted 2,6-dimethyl3,5-bis(alkoxycarbonyl)-1,4-dihydropyridines by human liver microsomes and immunochemical evidence for the involvement of a form of cytochrome P-450, J. Med. Chem. 29: 1596–1603.
Andersson, T., Miners, J. O., Veronese, M. E., and Birkett, D. J., 1993, Primary and secondary metabolism of omeprazole in human liver microsomes, in: Abstracts, 5th European ISSX Meeting (September 26–29, Tours), Vol. 3, p. 45.
Waxman, D. J., Attisano, C., Guengerich, E R, and Lapenson, D. R, 1988, Cytochrome P-450 steroid hormone metabolism catalyzed by human liver microsomes, Arch. Biochem. Biophys. 263: 424–436.
Mulford, D. J., Rodrigues, A. D., and Bopp, B. A., 1993, Identification of the human cytochrome P450 enzymes involved in the N-dealkylation of [14C]sertindole, in: Abstracts, 5th North American ISSX Meeting (October 17–21, Tucson), Vol. 4, p. 147.
Mitra, A. K., Kalhorn, T. F., Thummel, K. E., Unadkat, J. D., and Slattery, J. T., 1993, Metabolism of arylamines by human liver microsomal cytochrome P450(s), in: Abstracts, 5th North American ISSX Meeting (October 17–21, Tucson), Vol. 4, p. 148.
Jacolot, F., Simon, I., Dreano, Y., Beaune, P., Riche, C., and Berthou, F., 1991, Identification of the cytochrome P450111A family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes, Biochem. Pharmacol. 41: 1911–1919.
Kumar, G. N., Thornburg, K. R., Walle, U. K., and Walle, T., 1993, Evidence for human liver microsomal CYP 3A mediated hydroxylation of taxol, in: Abstracts, 5th North American ISSX Meeting (October, Tucson), Vol. 4, p 145.
Yun, C. H., Okerholm, R. A., and Guengerich, F. R, 1993, Oxidation of the antihistaminic drug terfenadine in human liver microsomes: Role of cytochrome P450 3A(4) in N-dealkylation and C-hydroxylation, Drug Metab. Dispos. 21: 403–409.
Aoyama, T., Yamano, S., Waxman, D. J., Lapenson, D. R, Meyer, U. A., Fischer, V., Tyndale, R, Inaba, T., Kalow, W., Gelboin, H. V., and Gonzalez, E J., 1989, Cytochrome P-450 hPCN3, a novel cytochrome P450 IIIA gene product that is differentially expressed in adult human liver, J. Biol. Chem. 264: 10388–10395.
Renaud, J. P., Cullin, C., Pompon, D., Beaune, P., and Mansuy, D., 1990, Expression of human liver cytochrome P450 IIIA4 in yeast: A functional model for the hepatic enzyme, Eur. J. Biochem. 194: 889–896.
Kroemer, H. K., Gautier, J.-C., Beaune, P., Henderson, C., and Wolf, C. R., 1993, Identification of P450 enzymes involved in metabolism of verapamil in humans, Naunyn-Schmiedebergs Arch. Pharmacol. 348: 332–337.
Ring, B. J., Parli, C. J., George, M. C., and Wrighton, S. A., 1993, Interspecies comparison and role of CYP3A in zatosetron metabolism, in: Abstracts, 5th North American ISSX Meeting (October 17–21, Tucson), Vol. 4, p. 36.
Nakasa, H., Komiya, M., Ohmori, S., Rikihisa, T., and Kitada, M., 1993, Rat liver microsomal cytochrome P-450 responsible for reductive metabolism of zonisamide, Drug Metab. Dispos. 21: 777–781.
Beaune, P. H., Umbenhauer, D. R., Bork, R. W., Lloyd, R. S., and Guengerich, E. P., 1986, Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase, Proc. Natl. Acad. Sci. USA 83: 8064–8068.
Elshourbagy, N. A., and Guzelian, P. S., 1980, Separation, purification, and characterization of a novel form of hepatic cytochrome P450 from rats treated with pregnenolone-l6a-carboni tri le, J. Biol. Chem. 255: 1279–1285.
Molowa, D. T., Schuetz, E.G., Wrighton, S. A., Watkins, P. B., Kremers, P., Mendez-Picon, G., Parker, G. A., and Guzelian, P. S., 1986, Complete eDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver, Proc. Natl. Acad. Sci. USA 83: 5311–5315.
Bork, R. W., Muto, T., Beaune, P. H., Srivastava, P. K., Lloyd, R. S., and Guengerich, F. P., 1989, Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity, J. Biol. Chem. 264: 910–919.
Kolars, J., Schmiedelin-Ren, P., Dobbins, W., Merion, R., Wrighton, S., and Watkins, P., 1990, Heterogeneity of P-450 ILIA expression in human gut epithelia, FASEB J. 4: A2242.
Daujat, M., Pichard, L., Fabre, I., Diaz, D., Maurice, M., Pineau, T., Blanc, P., Fabre, G., Fabre, J. M., Saint Aubert, B., and Maurel, P., 1990, Human P450IA and IIIA subfamilies: Regulation of expression and inducibility in primary cultures of human hepatocytes, in: Drug Metabolizing Enzymes: Genetics, Regulation and Toxicology, Proceedings of the Eighth International Symposium on Microsomes and Drug Oxidations (Stockholm, June 25–29) (M. Ingelman-Sundberg, J.-A. Gustafsson, and S. Orrenius, eds.), p. 16.
Schuetz, J. D., Molowa, D. T., and Guzelian, P. S., 1989, Characterization of a eDNA encoding a new member of the glucocorticoid-responsive cytochromes P450 in human liver, Arch. Biochem. Biophys. 274: 355–365.
Wrighton, S. A., Ring, B. J., Watkins, P. B., and VandenBranden, M., 1989, Identification of a polymorphically expressed member of the human cytochrome P-450III family, Mol. Pharmacol. 86: 97–105.
Wrighton, S. A., Brian, W. R., Sari, M. A., Iwasaki, M., Guengerich, E P., Raucy, J. L., Molowa, D. T., and VandenBranden, M., 1990, Studies on the expression and metabolic capabilities of human liver cytochrome P4501IIA5 (HLp3), Mol. Pharmacol. 38: 207–213.
Kitada, M., Kamataki, T., Itahashi, K., Rikihisa, T., Kato, R., and Kanakubo, Y., 1985, Purification and properties of cytochrome P-450 from homogenates of human fetal livers, Arch. Biochem. Biophys. 241: 275–280.
Komori, M., Nishio, K., Kitada, M., Shiramatsu, K., Muroya, K., Soma, M., Nagashima, K., and Kamataki, T., 1990, Fetus-specific expression of a form of cytochrome P-450 in human livers, Biochemistry 29: 4430–4433.
Schuetz, J. D., Kauma, S., and Guzelian, P. S., 1993, Identification of the fetal liver cytochrome CYP3A7 in human endometrium and placenta, J. Clin. Invest. 92: 1018–1024.
Hancock, R. L., 1992, Theoretical mechanisms for synthesis of carcinogen-induced embryonic proteins: XXVII. Intermediate generalizations (Part B), Med. Hypoth. 37: 6–1 I.
Hashimoto, H., Toide, K., Kitamura, R., Fujita, M., Tagawa, S., Itoh, S., and Kamataki, T., 1993, Gene structure of CYP3A4, an adult-specific form of cytochrome-P450 in human livers, and its transcriptional control, Eur. J. Biochem. 218: 585–595.
Kelly, J. D.,Eaton, D. L., Guengerich, F. P., and Coulombe, R. A., Jr., 1995, Aflatoxin B1 activation in human lung: Role of cytochrome P450 3A, Carcinogenesis, in press.
Kolars, J. C., Awni, W. M., Merion, R. M., and Watkins, P. B., 1991, First-pass metabolism of cyclosporin by the gut, Lancet 338: 1488–1490.
Schwab, G. E., Raney, J. L., and Johnson, E. F., 1988, Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by a-naphthoflavone, Mol. Pharmacol. 33: 493499.
Imaoka, S., Lmai, Y., Shimada, T., and Funae, Y., 1992, Role of phospholipids in reconstituted cytochrome P450 3A forms and mechanism of their activation of catalytic activity, Biochemistry 31: 6063–6069.
Peyronneau, M. A., Renaud, J. P., Truan, G., Urban, P., Pompon, D., and Mansuy, D., 1992, Optimization of yeast-expressed human liver cytochrome-P450 3A4 catalytic activities by coexpressing NADPH-cytochrome P450 reductase and cytochrome b5, Eur. J. Biochem. 207: 109–116.
Guengerich, F. P., 1995, Cytochrome P450s of human liver. Classification and activity profile of the major enzymes, in: Advances in Drug Metabolism in Man ( G. M. Pacifici and G. N. Fracchia, eds.), Medical Research Commission, European Communities, Brussels, pp. 179–231.
Buening, M. K., Fortner, J. G., Kappas, A., and Conney, A. H., 1978, 7,8-Benzoflavone stimulates the metabolic activation of aflatoxin Bi to mutagens by human liver, Biochem. Biophys. Res. Commun. 82: 348–355.
Buening, M. K., Chang, R. L., Huang, M. R., Former, J. G., Wood, A. W., and Conney, A. H., 1981, Activation and inhibition of benzo(a)pyrene and aflatoxin Bi metabolism in human liver microsomes by naturally occurring flavonoids, Cancer Res. 41: 67–72.
Shimada, T., and Guengerich, F. P., 1989, Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver, Proc. Natl. Acad. Sci. USA 86: 462–465.
Shimada, T., Iwasaki, M., Martin, M. V., and Guengerich, F. P., 1989, Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by mu gene response in Salmonella typhimurium TA1535/pSK1002, Cancer Res. 49: 3218–3228.
Raney, K. D., Shimada, T., Kim, D.-H., Groopman, J. D., Harris, T. M., and Guengerich, F. P., 1992, Oxidation of aflatoxin Bi and related dihydrofurans by human liver microsomes: Significance of aflatoxin QI as a detoxication product, Chem. Res. Toxicol. 5: 202–210.
Guengerich, F. P., Kim, B.-R., Gillam, E. M. J., and Shimada, T., 1994, Mechanisms of enhancement and inhibition of cytochrome P450 catalytic activity, in: Proceedings, 8th Int. Conf. on Cytochrome P450: Biochemistry, Biophysics, and Molecular Biology, ( M. C. Lechner, ed.) John Libbey Eurotext, Chichester, U.K., pp. 97–101.
Huang, M. T., Johnson, E. F., Muller-Eberhard, U., Koop, D. R., Coon, M. J., and Conney, A. H., 1981, Specificity in the activation and inhibition by flavonoids of benzo[a)pyrene hydroxylation by cytochrome P-450 isozymes from rabbit liver microsomes, J. Biol. Chem. 256: 10897–10901.
Johnson, E. F., Schwab, G. E., and Vickery, L. E., 1988, Positive effectors of the binding of an active site-directed amino steroid to rabbit cytochrome P-450 3c, J. Biol. Chem. 263: 17672–17677.
Rao, M. S., and Reddy, J. K., 1991, An overview of peroxisome proliferator-induced hepatocarcinogenesis, Environ. Health Perspect. 93: 205–209.
Gibson, G. G., 1993, Peroxisome proliferators: Paradigms and prospects, Toxicol. Lett. 68: 193–201.
Roman, L. J., Palmer, C.N.A., Clark, J. E., Muerhoff, A. S., Griffin, K. J., Johnson, E. F., and Masters, B.S.S., 1993, Expression of rabbit cytochromes P4504A which catalyze the to-hydroxylation of arachidonic acid, fatty acids, and prostaglandins, Arch. Biochem. Biophys. 307: 57–65.
Nhamburo, P. T., Gonzalez, F. J., McBride, O. W., Gelboin, H. V., and Kimura, S., 1989, Identification of a new P450 expressed in human lung: Complete cDNA sequence, cDNA-directed expression, and chromosome mapping, Biochemistry 28: 8060–8066.
Haurand, M., and Ullrich, V., 1985, Isolation and characterization of thromboxane synthase from human platelets as a cytochrome P450 enzyme, J. Biol. Chem. 260: 15059–15067.
Nüsing, R., Schneider-Voss, S., and Ullrich, V., 1990, Immunoaffinity purification of human thromboxane synthase, Arch. Biochem. Biophys. 280: 325–330.
Graf, H., Ruf, H. H., and Ullrich, V., 1983, Prostacyclin synthase, a cytochrome P450 enzyme, Angew. Chem. Int. Ed. Engl. 22: 487–488.
Ullrich, V., and Graf, H., 1984, Prostacyclin and thromboxane synthase as P-450 enzymes, Trends Pharmacol. Sci. 5: 352–355.
Hecker, M., and Ullrich, V., 1989, On the mechanism of prostacyclin and thromboxane A2 biosynthesis, J. Biol. Chem. 264: 141–150.
Hecker, M., Haurand, M., Ullrich, V., and Terao, S., 1986, Spectral studies on structure—activity relationships of thromboxane synthase inhibitors, Eur. J Biochem. 157: 217–223.
Danielsson, H., and Sjövall, J., 1975, Bile acid metabolism, Annu Rev. Biochem. 44: 233–253.
Li, Y. C., Wang, D. P., and Chiang, J. Y. L., 1990, Regulation of cholesterol 7a-hydroxylase in the liver: Cloning, sequencing, and regulation of cholesterol 7a-hydroxylase mRNA, J. Biol. Chem. 265: 12012–12019.
Pendak, W. M., Li, Y. C., Chiang, J. Y. L., Studer, E. J., Gurley, E. C., Heuman, D. M., Vlahcevic, Z. R., and Hylemon, R. B., 1991, Regulation of cholesterol 7a-hydroxylase mRNA and transcriptional activity by taurocholate and cholesterol in the chronic biliary diverted rat, J. Biol. Chem. 266: 34163421.
Nishimoto, M., Noshiro, M., and Okuda, K., 1993, Structure of the gene encoding human liver cholesterol 7a-hydroxylase, Biochim. Biophys. Acta 1172: 147–150.
Morohashi, K., Sogawa, K., Omura, T., and Fujii-Kuriyama, Y., 1987, Gene structure of human cytochrome P-450(SCC), cholesterol desmolase, J. Biochem. 101: 879–887.
Lin, D., Gitelman, S. E., Saenger, P., and Miller, W. L., 1991, Normal genes for the cholesterol side chain cleavage enzyme, P450., in congenital lipoid adrenal hyperplasia, J Clin. Invest. 88: 1955–1962.
Lauber, M., Sugano, S., Ohnishi, T., Okamoto, M., and Müller, J., 1987, Aldosterone biosynthesis and cytochrome P4504: Evidence for two different forms of the enzyme in rats, J. Steroid Biochem. 26: 693–698.
Lorence, M. C., Trant, J. M., Clark, B. J., Khyatt, B., Mason, J. I., Estabrook, R. W., and Waterman, M. R., 1990, Construction and expression of human/bovine P45017a chimeric proteins: Evidence for distinct tertiary structures in the same P450 from two different species, Biochemistry 29: 9819–9824.
Swart, P., Swart, A. C., Waterman, M. R., Estabrook, R. W., and Mason, J. I., 1993, Progesterone 16a-hydroxylase activity is catalyzed by human cytochrome P450 17a-hydroxylase, J. Clin. Endocrinol. Metab. 77: 98–102.
Yanase, T., Kagimoto, M., Matsui, N., Simpson, E. R., and Waterman, M. R., 1988, Combined 17a-hydroxylase/17,20-lyase deficiency due to a stop codon in the N-terminal region of 17a-hydroxylase cytochrome P-450, Mol. Cell. Endocrino!. 59: 249–253.
Kagimoto, M., Winter, J.S.D., Kagimoto, K., Simpson, E. R., and Waterman, M. R., 1988, Structural characterization of normal and mutant human steroid 17a-hydroxylase genes: Molecular basis of one example of combined 17a-hydroxylase/17,20 lyase deficiency, Mol. Endocrinol. 2: 564–570.
Yanase, T., Kagimoto, M., Suzuki, S., Hashiba, K., Simpson, E. R., and Waterman, M. R., 1989, Deletion of a phenylalanine in the N-terminal region of human cytochrome P-45017a results in partial combined 17a-hydroxylase/17,20-lyase deficiency, J. Biol. Chem. 264:18076–18082.
Yanase, T., Imai, T., Simpson, E. R., and Waterman, M. R., 1992, Molecular basis of 17a-hydroxylase/17,20-lyase deficiency, J. Steroid Biochem. Mol. Biol. 43: 973–979.
Ryan, K. J., 1958, Conversion of androstenedione to estrone by placental microsomes, Biochim. Biophys. Acta 27: 658–662.
Brodie, A. M. H., 1987, Aromatase inhibitors: Applications of inhibitors of estrogen biosynthesis, IS/ Atlas of Science: Pharmacology 266–269.
Kellis, J. T., Jr.., and Vickery, L. E., 1987, Purification and characterization of human placental aromatase cytochrome P-450, J. Biol. Chem. 262: 4413–4420.
Chen, S., Besman, M. J., Shively, J. E., Yanagibashi, K., and Hall, P. F., 1989, Human aromatase, Drug Metab. Rev. 20: 511–517.
Oh, S.S., and Robinson, C. H., 1993, Mechanism of human placental aromatase: A new active site model, J. Steroid Biochem. Mol. Biol. 44: 389–397.
Tan, L., and Muto, N., 1986, Purification and reconstitution properties of human placental aromatase: A cytochrome P450-type monooxygenase, Eur. J. Biochem. 157: 243–250.
Hall, P. F., Chen, S., Nakajin, S., Shinoda, M., and Shively, J. E., 1987, Purification and characterization of aromatase from human placenta, Steroids 50: 37–50.
Chen, S., Shively, J. E., Nakajin, S., Shinoda, M., and Hall, P. F., 1986, Amino terminal sequence analysis of human placenta aromatase, Biochem. Biophys. Res. Commun. 135: 713–179.
Mendelson, C. R., Wright, E. E., Evans, C. T., Porter, J. C., and Simpson, E. R., 1985, Preparation and characterization of polyclonal and monoclonal antibodies against human aromatase cytochrome P-450 (P-450arom), and their use in its purification, Arch. Biochem. Biophys. 243: 480–491.
Yoshida, N., and Osawa, Y., 1991, Purification of human placental aromatase cytochrome P-450 with monoclonal antibody and its characterization, Biochemistry 30: 3003–3010.
Corbin, C. J., Graham-Lorence, S., McPhaul, M., Mason, J. I., Mendelson, C. R., and Simpson, E. R., 1988, Isolation of a full-length cDNA insert encoding human aromatase system cytochrome P-450 and its expression in nonsteroidogenic cells, Proc. Natl. Acad. Sci. USA 85: 8948–8952.
Toda, K., Terashima, M., Kawamoto, T., Sumimoto, H., Yokoyama, Y., Kuribayashi, I., Mitsuuchi, Y., Maeda, T., Yamamoto, Y., Sagara, Y., Ikeda, H., and Shizuta, Y., 1990, Structural and functional characterization of human aromatase P-450 gene, Eur. J. Biochem. 193: 559–565.
Toda, K., and Shizuta, Y., 1994, Identification and characterization of cis-acting regulatory elements for the expression of the human aromatase cytochrome P-450 gene, J. Biol. Chem. 269: 8099–8107.
Toda, K., and Shizuta, Y., 1993, Molecular cloning of a cDNA showing alternative splicing of the 5’-untranslated sequence of mRNA for human aromatase P-450, Eur. J. Biochem. 213: 383–389.
Harada, N., 1992, A unique aromatase (P-450AROm) mRNA formed by alternative use of tissue-specific exons 1 in human skin fibroblasts, Biochem. Biophys. Res. Commun. 189: 1001–1007.
Harada, N., Utsumi, T., and Takagi, Y., 1993, Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis, Proc. Natl. Acad. Sci. USA 90: 11312–11316.
Guengerich, F. P., and Macdonald, T. L., 1993, Sequential electron transfer oxidation reactions catalyzed by cytochrome P-450 enzymes, in: Advances in Electron Transfer Chemistry, Vol. 3 (P. S. Mariano, ed.), JAI Press, Greenwich, CT, pp. 191–241.
Ortiz de Montellano, P. R., 1986, Oxygen activation and transfer, in: Cytochrome P-450 ( P. R. Ortiz de Montellano, ed.), Plenum Press, New York, pp. 217–271.
Cole, P. A., and Robinson, C. H., 1988, A peroxide model reaction for placental aromatase, J. Am. Chem. Soc. 110: 1284–1285.
Akhtar, M., Calder, M. R., Corina, D. L., and Wright, J. N., 982, Mechanistic studies on C-19 demethylation in oestrogen biosynthesis, Biochem. J. 201: 569–580.
Cole, P. A., and Robinson, C. H., 1990, Mechanism and inhibition of cytochrome P-450 aromatase, J. Med. Chem. 33: 2933–2942.
Cole, R A., and Robinson, C. H., 1991, Mechanistic studies on a placental aromatase model reaction, J. Am. Chem. Soc. 113: 8130–8137.
Vaz, A. D. N., Roberts, E. S., and Coon, M. J., 1991, Olefin formation in the oxidative deformylation of aldehydes by cytochrome P-450. Mechanistic implications for catalysis by oxygen-derived peroxide, J. Am. Chem. Soc. 113: 5886–5887.
Brodie, A. M. H., Banks, P. K., Inskster, S. E., Dowsett, M., and Coombes, R. C., 1990, Aromatase inhibitors and hormone-dependent cancers, J. Steroid Biochem. Mol. Biol. 37: 327–333.
Bhamagar, A. S., Häusler, A., Schieweck, K., Browne, L. J., Bowman, R., and Steele, R. E., 990, Novel aromatase inhibitors, J. Steroid Biochem. Mol. Biol. 37: 363–367.
Kellis, J. T., Jr., and Vickery, L. E., 1984, Inhibition of human estrogen synthetase (aromatase) by flavones, Science 225:1032–1034.
Kellis, J. T., Jr., Nesnow, S., and Vickery, L. E., 1986, Inhibition of aromatase cytochrome P-450 (estrogen synthetase) by derivatives of a-naphthoflavone, Biochem. Pharmacol. 35: 2887–2891.
Shimozawa, O., Sakaguchi, M., Ogawa, H., Harada, N., Mihara, K., and Omura, T., 1993, Core glycosylation of cytochrome P-405(arom): Evidence for localization of N terminus of microsomal cytochrome P-450 in the lumen, J. Biol. Chem. 268: 21399–21402.
Chen, S., Zhou, D., Swiderek, K. M., Kadohama, N., Osawa, Y., and Hall, P. F., 1993, Structure-function studies of human aromatase, J. Steroid Biochem. Mol. Biol. 44: 347–356.
Zhou, D., Pompon, D., and Chen, S., 1991, Structure-function studies of human aromatase by site-directed mutagenesis: Kinetic properties of mutants Pro-308 Phe, Tyr-361 Phe, Tyr-361 Leu, and Phe-406 Arg, Proc. Natl. Acad. Sci. USA 88: 410–414.
Graham-Lorence, S., Khalil, M. W., Lorence, M. C., Mendelson, C. R., and Simpson, E. R., 1991, Structure-function relationships of human aromatase cytochrome P-450 using molecular modeling and site-directed mutagenesis, J. Biol. Chem. 266: 11939–11946.
Chen, S., and Zhou, D., 1992, Functional domains for aromatase cytochrome P450 inferred from comparative analyses of amino acid sequences and substantiated by site-directed mutagenesis experiments, J. Biol. Chem. 267: 22587–22594.
Laughton, C. A., 1993, A detailed molecular model for human aromatase, J. Steroid Biochem. Mol. Biol. 44: 399–407.
Kagawa, N., and Waterman, M. R., 1991, Evidence that an adrenal-specific nuclear protein regulates the cAMP responsiveness of the human CYP21B (P450C21) gene, J. Biol. Chem. 266: 11199–11204.
Higashi, Y., Yoshioka, H., Yamane, M., Gotoh, O., and Fujii-Kuriyama, Y., 1986, Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: A pseudo-gene and a genuine gene, Proc. Natl. Acad. Sci. USA 83: 2841–2845.
Gitelman, S. E., Bristow, J., and Miller, W. L., 1992, Mechanism and consequences of the duplication of the human C4/P450c21/gene X locus, Mol. Cell. Biol. 12: 2124–2134.
Higashi, Y., Tanae, A., Inoue, H., and Fujii-Kuriyama, Y., 1988, Evidence for frequent gene conversion in the steroid 21-hydroxylase P-450(C21) gene: Implications for steroid 21-hydroxylase deficiency, Am. J. Hum. Genet. 42: 17–25.
Helmberg, A., Tabarelli, M., Fuchs, M. A., Keller, E., Dobler, G., Schnegg, I., Knorr, D., Albert, E., and Kofler, R., 1992, Identification of molecular defects causing congenital adrenal hyperplasia by cloning and differential hybridization of polymerase chain reaction-amplified 21-hydroxylase (CYP21) genes, DNA Cell Biol. 11: 359–368.
Chiou, S. H., Hu, M. C., and Chung, B., 1990, A missense mutation at Ile 172-Asn or Arg356-*Trp causes steroid 21-hydroxylase deficiency, J. Biol. Chem. 265: 3549–3552.
New, M. I., 1994, 21-Hydroxylase deficiency congenital adrenal hyperplasia, J. Steroid Biochem. Mol. Biol. 48: 15–22.
Cali, J. J., and Russell, D. W., 1991, Characterization of human sterol 27-hydroxylase: Amitochondrial cytochrome P-450 that catalyzes multiple oxidation reactions in bile acid biosynthesis, J. Biol. Chem. 266: 7774–7778.
Cali, J. J., Hsieh, C. L., Francke, U., and Russell, D. W., 1991, Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis, J. Biol. Chem. 266: 7779–7783.
Ishida, N., Aoyama, Y., Hatanaka, R., Oyama, Y., Imajo, S., Ishiguro, M., Oshima, T., Nakazato, H., Noguchi, T., Maitra, U.S., Mohan, V. P., Sprinson, D. B., and Yoshida, Y., 1988, A single amino acid substitution converts cytochrome P45014DM to an inactive form, cytochrome P450SG1: Complete primary structures deduced from cloned DNAs, Biochem. Biophys. Res. Commun. 155: 317–323.
Aoyama, Y., Yoshida, Y., Nishino, T., Katsuki, H., Maitra, U. S., Mohan, V. P., and Sprinson, D. B., 1987, Isolation and characterization of an altered cytochrome P-450 from a yeast mutant defective in lanosterol 14a-demethylation, J. Biol. Chem. 262: 14260–14264.
Coles, B. E, Welch, A. M., Hertzog, P. J., Lindsay Smith, J. R., and Garner, R. C., 1980, Biological and chemical studies on 8,9-dihydroxy-8,9-dihydro-aflatoxin B1 and some of its esters, Carcinogenesis 1: 79–90.
Poulos, T. L., Finzel, B. C., and Howard, A. J., 1987, High-resolution crystal structure of cytochrome P450cam, J. Mol. Biol. 195: 687–700.
Ravichandran, K. G., Boddupalli, S. S., Hasemann, C. A., Peterson, J. A., and Deisenhofer, J., 1993, Crystal structure of hemoprotein domain of P450 BM-3, a prototype for microsomal P450’s, Science 261: 731–736.
Hasemann, C. A., Ravichandran, K. G., Peterson, J. A., and Deisenhofer, J., 1994, Crystal structure and refinement of cytochrome P450(terp) at 2.3 angstrom resolution, J. Mol. Biol. 236: 1169–1185.
Poulos, T. L., 1991, Modeling of mammalian P450s on basis of P450cam X-ray structure, Methods Enzymol. 206: 11–30.
Crespi, C. L., Langenbach, R., and Penman, B. W., 1993, Human cell lines, derived from AHH-1 TK+/— human lymphoblasts, genetically engineered for expression of cytochromes P450, Toxicology 82: 89–104.
Schmalix, W. A., Mäser, H., Kiefer, F., Reen, R., Wiebel, F. J., Gonzalez, F., Seidel, A., Glatt, H., Greiff’, H., and Doehmer, J., 1994, Stable expression of human cytochrome P450 lAl cDNA in V79 Chinese hamster cells and metabolic activation of benzo[a]pyrene, Eur. J. Pharmacol. 248: 251–261.
Larson, J. R., Coon, M. J., and Porter, T. D., 1991, Alcohol-inducible cytochrome P-45011E1 lacking the hydrophobic NH2-terminal segment retains catalytic activity and is membrane-bound when expressed in Escherichia coli, J. Biol. Chem. 266: 7321–7324.
Barnes, H. J., Arlotto, M. P., and Waterman, M. R., 1991, Expression and enzymatic activity of recombinant cytochrome P450 17a-hydroxylase in Escherichia coli, Proc. Natl. Acad. Sci. USA 88: 5597–5601.
Kinirons, M. T., Oshea, D., Downing, T. E., Fitzwilliam, A. T., Joellenbeck, L., Groopman, J. D., Wilkinson, G. R., and Wood, A. J. J., 1993, Absence of correlations among 3 putative in vivo probes of human cytochrome-P4503A activity in young healthy men, Clin. Pharmacol. Ther. 54: 621–629.
Mueller, G. C., and Miller, J. A., 1953, The metabolism of methylated aminoazo dyes. II. Oxidative demethylation by rat liver homogenates, J. Biol. Chem. 202: 579–587.
Richardson, H. L., Stier, A. R., and Borsos-Nachtnebel, E., 1952, Liver tumor inhibition and adrenal histologic responses in rats to which 3’-methyl-4-dimethylaminoazobenzene and 20-methylcholan-threne were simultaneously administered, Cancer Res. 12: 356–361.
Miller, E. C., Miller, J. A., and Conney, A. H., 1954, On the mechanism of the methylcholanthrene inhibition of carcinogenesis by 3’-methyl-4-dimethylaminoazobenzene, Proc. Am. Assoc. Cancer Res. 1: 32.
Miller, E. C., Miller, J. A., Brown, R. R., and MacDonald, J. C., 1958, On the protective action of certain polycyclic aromatic hydrocarbons against carcinogenesis by aminoazo dyes and 2-acetylaminofluorene, Cancer Res. 18: 469–477.
Conney, A. H., Miller, E. C., and Miller, J. A., 1956, The metabolism of methylated aminoazo dyes. V. Evidence for induction of enzyme synthesis in the rat by 3-methylcholanthrene, Cancer Res. 16: 450–459.
Nebert, D. W., 1978, Genetic control of carcinogen metabolism leading to individual differences in cancer risk, Biochimie 60: 1019–1029.
Nebert, D. W., 1989, The Ah locus: Genetic differences in toxicity, cancer, mutation, and birth defects, Crit. Rev. Toxicol. 20: 153–174.
Guengerich, F. P., 1988, Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy, Cancer Res. 48: 2946–2954.
Guengerich, E. P., 1990, Characterization of roles of human cytochrome P450 enzymes in carcinogen metabolism, Asia Pac. J. Pharmacol. 5: 327–345.
Guengerich, F. P., 1992, Metabolic activation of carcinogens, Pharmacol. Ther. 54: 17–61.
Guengerich, F. P., 1993, The 1992 Bernard B. Brodie Award Lecture. Bioactivation and detoxication of toxic and carcinogenic chemicals, Drug Metab. Dispos. 21: 1–6.
Yamazaki, H., Mimura, M., Oda, Y., Inui, Y., Shiraga, T., Iwasaki, K., Guengerich, P. R, and Shimada, T., 1993, Roles of different forms of cytochrome P450 in the activation of the promutagen 6-aminochrysene to genotoxic metabolites in human liver microsomes, Carcinogenesis 14: 1271–1278.
Caporaso, N. E., Shields, P. G., Landi, M. T., Shaw, G. L., Tucker, M. A., Hoover, M., Sugimura, H., Weston, A., and Harris, C. C., 1992, The debrisoquine metabolic phenotype and DNA-based assays: Implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype, Environ. Health Perspect. 98: 101–105.
Uematsu, F., Kikuchi, H., Motomiya, M., Abe, T., Sagami, I., Ohmachi, T., Wakui, A., Kanamaru, and Watanabe, M., 1991, Association between restriction fragment length polymorphism of the human cytochrome P4501IE1 gene and susceptibility to lung cancer, Jpn. J Cancer Res. 82: 254–256.
Kirby, G. M., Wolf, C. R, Neal, G. E., Judah, D. J., Henderson, C. J., Srivatanakul, P., and Wild, C. P., 1993, In vitro metabolism of aflatoxin Bt by normal and tumorous liver tissue from Thailand, Carcinogenesis 14: 2613–2620.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Guengerich, F.P. (1995). Human Cytochrome P450 Enzymes. In: de Montellano, P.R.O. (eds) Cytochrome P450. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-2391-5_14
Download citation
DOI: https://doi.org/10.1007/978-1-4757-2391-5_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-3248-8
Online ISBN: 978-1-4757-2391-5
eBook Packages: Springer Book Archive